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ABSTRACT
Particulate drug delivery systems are gaining considerable attention in recent years due to
increasing advantages for an effective delivery of therapeutics. Application of advanced particle
engineering technologies in polymeric drug delivery systems has shown to improve the efficacy
of a drug substance by maintaining stable levels in the blood when compared to traditional
parenteral drug products. However, development of these products is a complex multifaceted
process with numerous challenges. Formulation development scientists need to comprehend and
control a range of unit manufacturing operations along with the formulation composition for a
successful product. Therefore, the objective of this project is to study the development of advanced
micro-and nano-sized drug products with minimum number of experiments using multivariate
statistical tools.
Chapter 1 provides background and literature on various polymers used in drug delivery and
particle engineering technologies to manufacture micro- and nano-sized drug products. It also
provides a comprehensive overview on various multivariate statistical tools that could be applied
in product development.
Chapter 2 compares the capabilities of principal component regression (PCR) and multiple
linear regression (MLR) to model and predict the impact of formulation and process parameters
on the metronidazole benzoate–ethyl cellulose microsponge particle properties. The observations
imply that MLR models showed relatively better predictability than PCR.
Chapter 3 reports the aerosolization of sildenafil citrate loaded polymeric microparticles
engineered using multivariate statistical tools by spray-drying (SD) and spray freeze-drying (SFD)
processes. Particles engineered by both SD and SFD demonstrate good aerosolization properties.
However, particles engineered by SD demonstrated relatively superior aerodynamic characteristics
than SFD
Chapters 4 and 5 reports gelatin nanoparticles (GNPs) engineered by desolvation using
multivariate statistical tools. About 20-40% of the low molecular weight (25 kD) fraction could
be eliminated by a desolvating ‘as is’ gelatin with acetone. Studies demonstrated statistically
significant (p<0.05) roles of gelatin solution pH and incubation times on the size and size
ii

distribution of the nanoparticles prepared by desolvation. Irrespective of gelatin grades, desolvated
gelatins produced GNPs with significantly (p=0.0287) lower size when compared to ‘as is’
gelatins. It is highly recommended to use freshly prepared gelatin solution to attain GNPs of
reproducible size.
Overall, these experimental findings show that selection of statistical design for particle
engineering is formulation and process dependent. Reproducibility of protein-based nanoparticles
are greatly influenced by starting material properties and sample composition prior to synthesis.
This study is anticipated to lay foundation for further exploration to develop a highly-controlled
processing technologies to engineer polymeric particulate drug delivery systems.
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Chapter 1 : BACKGROUND AND LITERATUR
1.1.Polymers in Drug Delivery
Polymers have been an integral part of several clinically approved drug products and played
an intrinsic role in the advancement of drug delivery technology.1 The drug release rate and extent
of biodegradation from polymeric particles can be amended by changing monomer
stereochemistry, polymer molecular weight, terminal end groups, amorphization, copolymer ratio,
and hydrophobicity.2 Hence, polymeric particles hold potential for precise control of particle
characteristics, increased hydrophobic drug loading, easy surface modification, enhanced systemic
bioavailability, and long-term drug release makes polymeric systems particularly attractive for
local as well as systemic therapeutics.3 Through nanotechnology, they further enable modifications
for optimized delivery of therapeutics, to overcome heterogenous biological barriers, in a more
personalized manner.3 Based on shape and orientation, the polymeric nanoparticles are subdivided
to polymersomes, dendrimers, polymeric micelles, and nanospheres.
The ideal characteristics of polymers for drug delivery include:
i.

Easy to manufacture, inexpensive, scalable, and commercially available

ii.

Physically and chemically stable under conditions such as high humidity, temperature, and
attrition

iii.

Biocompatible, biodegradable, and show low cytotoxicity

iv.

Suitable for all types of modalities and not trigger immune response

v.

Able to deliver cargo, either small- or macro-molecules, to a target cell type, even when
they are part of a heterogeneous population

vi.

Able to withstand and overcome physiological barriers
Numerous natural polymers, synthetic polymers, and copolymers has been studied as carriers

for drug delivery.1, 4, 5 Table 1-1 summarizes the list of widely used polymers in Food and Drug
Administration (FDA) approved drug products. The widely used natural polymers include
albumin, chitosan, gelatin, and hyaluronic acid. The commonly used synthetic polymers are
poly(lactic acid) [PLA], poly(ethylene glycol) [PEG], polyvinyl alcohol (PVA), and acrylic acid

1

derivatives. Poly(lactic-co-glycolic acid) [PLGA] is the most frequently used copolymer in diverse
drug products. These copolymers are the multiple subunits of two or more different monomers that
offer greater flexibility for diverse pharmaceutical applications. Unlike the rest of the polymers,
PEG is usually added to increase the molecular weight of drug substance, enhance
mucopenetration of a drug product, and sustain the release of a drug substance from drug product.6
Occasionally, two or more polymers could be conjugated to enhance the delivery of cargo to the
target site.7-9
Table 1-1. Polymers in FDA approved drug products
Natural
• Albumin (for IV, SC, IM, oral, topical use)
polymers
• Alginic acid (for ophthalmic and oral use)
• Cellulose (MicroceLac®)
• Chitosan
• Collagen (for topical use)
• Dextran
• Gelatin (for IM, SC, IV, oral, topical use)
• Hyaluronic acid (for intra-articular, IM, intravitreal, topical use)
• Starch (for oral, IV, IM, topical use)
Semi• Cellulose derivative (Hydroxy methyl cellulose; hydroxy propyl methyl
synthetic
cellulose; carboxymethyl cellulose)
polymers
• Starch derivatives (Glycolys®; Hydroxy ethyl cellulose)
• Glycopolymers
Synthetic
• Poly(lactic acid) [for IM use]
polymers
• Poly(lactic-co-glycolic acid) [for IM, SC use]
• Poly(ethylene glycol) [oral, respiratory, topical, IM, IV, ophthalmic use]
• Poly(vinyl acetate)
• Poly(vinyl alcohol)
• Poloxamer (for oral, topical, IV, ophthalmic, SC use)
• Methacrylic acid derivative (Eudragit®)
Polymer development for drug delivery is a challenging procedure. It requires the
complementary application of chemistry, pharmaceutical sciences, and molecular biology. Several
polymeric systems for various routes of administration are reported in literature10-13, but very few
found their translation to the clinic. One major challenge is to establish their in vitro and in vivo
performance correlation. Any polymeric drug carrier, either micro- or nano-particle, entering
systemic circulation, is not only required to be biocompatible, biodegradable, and non-toxic, but
also possess the ability to overcome substantial challenges posed by pulmonary or systemic
2

barriers. These are categorized to material, formulation development, and physiological challenges
(Table 1-2). Material thermotropic behavior is the primary source of variability that has potential
impact on finished product. Strategies like annealing and application of experimental design on
drug product development have been suggested to mitigate the impact of raw material
variability.14-16
Table 1-2. Challenges in Polymeric Carriers Preclinical Development
Material challenges • Selection of excipients that are compatible and degradable in vivo
• Selection of polymer based on desired site of action, especially in case
of stimuli responsive systems
• Minimize effect of variability within polymer properties during
formulation process and final product
Formulation
• Ability to apply Quality by Design (QbD) based risk assessment
development
• Safety and compatibility with product delivery device
challenges
• Feasibility to scale up to the manufacturing process
• Pharmacokinetic (PK) – pharmacodynamic (PD) relationships
Physiological
• Instability due to plasma proteins in the blood circulation
challenges
• Opsonization and rapid clearance by the reticuloendothelial system
and mucociliary transport epithelial cells
• Poor cell uptake or internalization
• Uptake by endosomes and/or lysosomes for degradation
• Disease condition
1.2.Particle Engineering in Polymeric Drug Delivery
Particulate drug delivery systems are gaining considerable attention in recent years due to
increasing advantages for an effective delivery of therapeutics. Early days of pharmaceutical
development involved extensive studies to mitigate poor solubility, specificity, therapeutic index
etc., of a drug substance. Shape and size modifications, by excipients or processes, have been
demonstrated to affect the pharmacokinetics and cellular interaction of a drug substance. 17-20
Hence, it is not surprising to see extensive research in this area in past decades.
Microtechnology and nanotechnology are the two advanced particle engineering methods that
changed the landscape of pharmaceutical industries in the 21 st century. Application of these
advanced particle engineering technologies in polymeric drug delivery systems has shown to
improve the efficacy of a drug substance by maintaining stable levels in the blood when compared
to traditional parenteral drug products.

3

1.2.1. Microscale particle engineering
Microtechnology in drug delivery systems involves engineering microscale carrier systems to
efficiently carry a drug substance to the desired site of action. Neoral ® is the first FDA approved
microscale drug product in 1995.21 It is an oral formulation of cyclosporine that immediately forms
a microemulsion in aqueous environment. Microscale polymeric drug product did not receive
regulatory approval until a decade after the approval of first microscale drug product. Vivitrol® is
the extended-release polymeric microsphere formulation of naltrexone for intramuscular
administration. It has been approved by the FDA in 2006.21 Naltrexone is incorporated in 75:25
PLGA at a concentration of 337 mg of naltrexone per gram of microspheres.22
1.2.2. Nanoscale particle engineering
Nanotechnology in drug delivery systems involves engineering nanoscale carrier systems to
efficiently carry a drug substance to the desired site of action. Furthermore, this technology enables
combination therapy and targeting delivery of therapeutic substances through chemical
modifications. Nanoscale drug products, including small molecule pharmaceuticals to
macromolecule biopharmaceuticals, have offered new approaches to the delivery of therapeutics
with minimal size effects. According to the United States (US)—FDA and the European Medical
Agency, a drug product may comprise the application of nanotechnology when- “(i) a material or
end product is engineered to have at least one external dimension, or an internal or surface
structure, in the nanoscale range (approximately 1 nm to 100 nm) and (ii) whether a material or
end product is engineered to exhibit properties or phenomena, including physical or chemical
properties or biological effects, that are attributable to its dimension(s), even if these dimensions
fall outside the nanoscale range, up to one micrometer (1,000 nm)”.23,
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Harmoniously,

nanomaterials might belong to various components of a drug product such as drug substance (eg.
nanocrystals), excipients (eg. drug substance complexation with metals, proteins, polymers etc.,).
A total of 359 drug product applications containing nanomaterials were submitted to the FDA’s
Center for Drug Evaluation and Research (CDER) between 1970 and 2015.25 This includes 65.2%
investigational new drugs (IND’s), 17.3% new drug applications (NDA’s), and 17.5% abbreviated
new drug application (ANDA’s). Approximately 80% of these applications containing
nanomaterials have average particle sizes of ~300 nm.25 About 33% of the overall applications
were for liposomal drug products. This was followed by nanocrystals and emulsions forming 23%
and 14% of the submissions. Despite extensive research coupled with tremendous advantages of
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protein-based polymeric nanoparticles as drug delivery carriers 26, less than 14% of them have been
translated to clinical trials and received regulatory approvals.
Nanotechnology concepts were applied in drug product even before the first liposome approval
to the clinic. Products like Intralipid ® emulsion, Gris-PEG® tablets, Proferdex® injection were
introduced before Doxil® liposomes. D’Mello et al. 25 provided a comprehensive list of CDER
approved NDA’s containing nanomaterials. Several gaps are seen from regulatory standpoint
despite the existence of nanotechnology applications for little over three decades. Some of the
unanswered elements include—nanomedicine classification/nomenclature, clarity on critical
characterization data for drug applications, validation procedures and specifications for in vitro
and in vivo analytical methods, preclinical and clinical quality criteria for market approvals.
1.2.3. Polymeric microparticle and nanoparticle engineering technologies
Tremendous progress has been made in polymeric particle engineering as a result of the
exploration of diffusion-controlled and solvent-activated formulations in drug delivery.1 Several
polymeric microparticle and nanoparticle engineering technologies are reported in literature. 27, 28
Based on underlying operating principles, these technologies can be categorized into: (i)
precipitation technology; (ii) high-pressure homogenization technology; (iii) spray-drying
technology; (iv) spray freeze-drying technology; and (v) milling technology. Some of these
technologies have been optimized for scalability as well as continuous manufacturing and
trademarked for commercialization (Table 1-3).
Table 1-3. Proprietary manufacturing technologies for nanosized drug products
Proprietary technique
Manufacturing methodology
Company
Insoluble Drug Delivery –
Microfluidic homogenization
SkyePharma
Particles (IDD-PTM)29
DissoCubesTM30
High pressure homogenization
SkyePharma
HydrosolTM31
Precipitation
Novartis
TM32
NanoCrystal
Media milling
Elan Nanosystems
NanoEdgeTM33
High pressure homogenization
Baxter
TM34
BioAqueous
Emulsification
Dow Pharma
NanoQUADTM35
Cryo-milling
Nanotherapeutics Inc.,
TM35
NanoDRY
-Nanotherapeutics Inc.,
TM35
NanoCOAT
-Nanotherapeutics, Inc.,
NanoMorphTM36
Precipitation
SOLIQS/Abbott
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1.2.3.1.

Precipitation

Precipitation technology is one of the oldest methods for the production of microparticles and
nanoparticles.28 Generally, drug substance along with polymeric material is dissolved in a solvent
and precipitated to dispersed drug-loaded polymeric particles by the addition of an antisolvent.
Based on type of materials used and order of addition, the precipitation technique is further
classified to desolvation, solvent evaporation, nanoprecipitation etc., HydrosolTM31 and
NanoMorphTM36 are the proprietary technologies designed based on the principle of precipitation.
Desolvation is a simple and widely reported process where in the polymeric materials dissolved
in an aqueous solvent are restructured upon dropwise addition of a desolvating agent, resulting in
the formation of spherical shaped particles.
Slowly added desolvating
Slowly added re~35°C agent (20% w/v aq. sodium ~35°C solvating agent (ethanol, ~35°C
sulfate, or 95% v/v ethanol
or isopropanol) until
until “permanently faintly
turbidity disappears
turbid”

Frozen in dry
ice/acetone bath and
FREEZE DRIED
overnight

Homogeniza
tion

~35°C

Added sodium
sulfite/metabisulfite, while
homogenizing, to REMOVE
excess glutaraldehyde and
STOP crosslinking

o pH adjusted in first 3 steps as needed
o Resolvation prevents rapid turbidity and flocculation upon glutaraldehyde addition
o Active pharmaceutical ingredient(s) addition• water soluble => aq. gelatin solution
• water insoluble => surfactant system
• alcohol soluble => desolvating agent

Nephelometer reading

1.0-3.0% w/v aq. gelatin
solution
+
0.5-3.0% w/v polysorbate
20 surfactant

~35°C

Homogeniza
tion

Added
25% w/v aq.
glutaraldehyde
solution while
homogenizing

Turbid
coacervate

Desolvation

Resolvation

Best suited for crosslinking

Marty et al (1978) Pharma Acta Helveticae. 53(1), 17-23.

Figure 1-1. Schematic of one-step desolvation process used to prepare gelatin nanoparticles 37
Figure 1-1 illustrates the schematic of one-step desolvation process used to prepare gelatin
nanoparticles. Aqueous polymeric solution comprises of a polymer and aqueous solvent in a single
phase that are electrostatically bound by hydrogen bonding. Addition of antisolvent or desolvating
agent, such as ethanol and acetone, initiates the breakdown of these hydrogen bond interactions
and replaces the water molecules surrounding the polymer with a desolvating agent. This
eventually leads to folding or restructuring of polymer fragments into particulate structures. If
surface crosslinking is necessary, the desolvated particulates are crosslinked with suitable bi- or
multi-functional chemical crosslinker to ingrain physical stability. Hence, desolvation is a
6

thermodynamically driven self-assembly technique because it increases the entropy of the final
system. The attributes of a finished product manufactured by desolvation are critically dependent
on the polymer concentration, type, processing temperature, concentration as well as type of
desolvating agent, addition flow rate of desolvating agent, and mixing speed.
Emulsification involves spontaneous mixing of the aqueous and oil phases in the presence of
an emulsifier, under controlled conditions of temperature and mechanical shear. This was first
described in gelatin nanoparticles preparation in 1981.38 The aqueous polymeric solution acts as a
dispersed phase and the emulsifier along with other non-aqueous oil components act as dispersion
medium. Hydrophilic API are encapsulated by dissolving in the aqueous component or a dispersed
phase. However, hydrophobic API molecules can be encapsulated through dispersion medium by
oil-water-oil emulsification. This involves hydrophobic molecule dissolution in the oil phase,
followed by emulsification with the aqueous dispersed phase and final emulsification with another
non-aqueous dispersion medium. The dispersion medium provides resistance to the charged
polymeric particles and prevents agglomeration, while, the emulsifiers reduce the interfacial
tension between the dispersed phase and dispersion medium during emulsification. Furthermore,
emulsifiers minimize the energy required to break aqueous polymeric solution into micro- or
nanoparticles. Homogenization or ultrasonication are commonly employed to provided high
mechanical shear. If needed, particles are crosslinked upon cooling. The final step involves
extensive purification to remove organic components with emulsifiers, excess chemical
crosslinker, and unentrapped API molecules.
Nanoencapsulation39 and solvent evaporation40 are the modified emulsification techniques.
Emulsifiers used in conventional emulsification may not be compatible to fragile therapeutic
substances like peptides or proteins as they stimulate competitive binding and denaturation. This
could not only alter the therapeutic efficacy but also the physicochemical properties of a drug
product. Nanoencapsulation is an emulsifier-free method where aqueous polymeric disperse phase
is homogenized in oil phase under high shear and temperature.39 On the contrary, solvent
evaporation involves the replacement of oil components with organic solvents in the dispersion
medium.
1.2.3.2.

High-Pressure Homogenization

High-pressure homogenization is a mechanical process, commonly used in preparing
polymeric particles loaded with poorly soluble APIs.28 Stabilizers are usually required to stabilize
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the polymeric particles in this process. Based on the equipment setup and manufacturing
conditions, they are further categorized to microfluidics homogenization and piston-gap
homogenization.28
Microfluidic homogenization uses microfluidizer setup for particle preparation. These are jetsteam homogenizers where two fluids collide under high pressure (1700 bar) and results in
particle formulations as well as size control due to shear forces and particles collisions.28 IDDPTM29 proprietary particle engineering technology was developed by applying the principles of
microfluidics homogenization.
Piston-gap homogenization uses cavitation forces created by high pressure homogenizer.28
This involves high shear mixing of various formulation components along with a stabilizer, usually
at 1500 bar pressure and 3-20 homogenization cycles.28 DissoCubesTM30 and NanoEdgeTM33 are
well known proprietary particle engineering technologies, developed by applying the principles of
piston-gap homogenization.
1.2.3.3.

Spray-Drying Technology

Spray drying works on the principle of evaporative cooling i.e. drying an atomized liquid by
hot compressed air flow. Figure 1-2 illustrate the schematic of a spray-drying process.
Spray drying is a scalable, controlled, robust, and pharmaceutically viable process to engineer
micron and submicron sized particles. The spray gas flows through into a drying chamber, which
enables the sample material to disperse in an atomized liquid state. High-velocity, heated air
coming from the aspirator drives off water from the atomized liquid; thereby, producing solid
particles. Primary separation of these particles takes place in the drying chamber, where more
dense particles are deposited into separation flask. Remaining particles pass into the cyclone
separator, where they get classified based on inertial forces. Particles of narrow size range gets
deposited in the collection vessel and lighter particles stick to glass walls due to electrostatics or
pass through with the outlet air filter. The sample material being sprayed can be a solution,
suspension, or an emulsion.
ExuberaTM, an inhalable insulin, is the first clinically approved spray-dried pharmaceutical
product targeting systemic treatment through the pulmonary delivery route.28
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Figure 1-2. Schematic illustration of a spray-drying process (Picture from Vinjamuri ©2015
thesis41)
Spray freeze-drying can be considered as a hybrid technology, applying the principles of spraydrying and freeze-drying. This involves freezing of atomized droplets followed by solvent removal
by sublimation process through freeze-drying. Spray freeze-drying has been investigated for
pharmaceutical applications since 1990s.28 The characteristics of a spray freeze-dried products,
upon removal of water, are dependent not only on the formulation composition but also on the
nature of droplet formulation and freezing process. 42 Unlike traditional lyophilization process,
spray freeze-drying facilitates controls of particles size and distribution, which makes it a favorable
process to engineer polymeric microparticles for pulmonary delivery.
1.2.3.4.

Milling Technology

Milling is another mechanical shear oriented process where the large particles are reduced to
microscale and nanoscale particles.28 Ball mill and Jet mill are the two predominantly used
equipment in milling technology. The shear input for each of these mills is different. Dry milling
is more commonly used in engineering microparticles, especially inhalable powders, than
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nanoparticles. However, it is known to create partially amorphous particles and results in
agglomeration. This issue can be mitigated by wet milling technique.28, 43
1.3.Gelatin Polymeric Nanoparticles in Drug Delivery
Gelatin has been an extensively investigated biodegradable natural protein among the proteinbased nanopharmaceuticals to deliver small- and macro-molecules.4 It is a partially hydrolyzed
peptide obtained by irreversible structural and chemical degradation of collagen. 44 The acid
hydrolysis of porcine skin collagen with an isoelectric point (IEP) between 7.0 and 9.5 results in
positively charged gelatin at a physiological pH 7.4. This cationic gelatin is commonly marketed
as Type A gelatin. The bovine skin gelatin has an IEP between 4.7 and 5.0. Alkaline treatment of
bovine sourced gelatin hydrolyzes the asparagine and glutamine groups to aspartate and glutamate;
consequently, resulting in a negatively-charged gelatin with higher proportion of carboxylate
groups at a physiological pH 7.4. This anionic gelatin is usually marketed as Type B gelatin.45
Overall, the hydrolysis results in gelling or non-gelling grades of gelatin of varied molecular
weights and physicochemical properties.

Figure 1-3. Structural illustration of [A] gelatin peptide and [B] amino-acid composition
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Figure 1-3 illustrates the chemical composition of gelatin. It is a heterogenous mixture of
several water-soluble amino-acids, with overall molecular weight ranging between 20-200 kD.46
Gelatin is amphoteric in nature because it contains amino-, carboxyl-, and hydroxyl- functional
groups. Glycine (~24%), proline (~17%), alanine (~14%), hydroxyproline (~10%), glutamic acid
(~7%), and aspartic acid (~6%) are the six major amino acids in gelatin. The remain amino acids
are less abundant.47 Unlike albumin, the essential amino acid tryptophan is absent in gelatin.
Numerous reviews outlined the prospects of gelatin as a carrier in drug delivery. 48-52 Despite
the mounting research and technical advancements triggered by the promising prospects, no gelatin
nanoparticles (GNPs) product has reached the clinic. This might be due to the numerous challenges
associated with protein-based formulation components and manufacturing procedures during the
early development.
Peptides like gelatin are susceptible to diminutive environmental changes like temperature,
pH, ionic strength etc., This poses stability concerns while handling during the manufacturing
process. Desolvation methods are widely used to engineer therapeutic agent loaded GNPs. 37, 53, 54
This down-stream manufacturing process involves numerous steps such as the use of organic
solvents, mixing, evaporation, crosslinking, centrifugation, filtration, lyophilization and
occasional sterilization. Previous studies have shown size modulations in the desolvation
procedure due to various reaction parameters such as desolvation steps 53, gelatin type55-59, gelatin
concentration60, gelatin solution pH54, 55, 57-59, 61, desolvating agent type55, 56, amount of desolvating
agent61, temperature55,

57,

crosslinker concentration54,

55, 62,

and crosslinking time54. However,

inscrutable reproducibility issues often tagged them. We believe, an in-depth understanding of the
interplay between the materials physicochemical attributes and processing conditions might be
fundamental to establish highly reproducible manufacturing procedures for GNPs production.
1.4.Multivariate Statistical Tools in Polymeric Particle Engineering for Drug Delivery
Application of multivariate statistical tools in current experimental research is not new. It
origins back to 1920’s by the work of a famous statistician, Sir Ronald Aylmer Fisher. 63 He
underlined the necessity to consider statistical analysis during early stages of experimentation in
his books “Statistical Methods for Research Workers”64, “Arrangement of Field Experiments”65,
and “The Design of Experiments”66. The work by Fisher has been expanded and followed for
engineering quality products in the subsequent years. His contributions have been the foundation
for modern statistical thinking in science and industrial applications. 63 However, it was William
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Edward Deming, an engineer/scholar in quality management, applied these statistical concepts to
instill quality in their overall operations and sparked the quality revolution.67 It was in 1992, the
term “Quality by Design” has been used for the first time by Juran. 68 Through his book, he
underlined the importance of implementing new strategies during the early stages of development
to instill quality into the goods and services.68
Pharmaceuticals, like many other fields, demands a proactive approach because the research is
principally process and quality oriented. These aspects during product development reveals the
undeniable capability of a finished product to meet the predefined safety and effectiveness
requirements extended by the regulatory agencies. Furthermore, lack of thorough planning and
data driven experimentation in the early stages of research and development could impose high
risk for product failures during scale-up, and eventually financial losses. Therefore, continuous
quality verification is crucial in pharmaceutical product formulation and process development,
especially during early stages, to avoid unforeseen economic losses.
Pharmaceutical sector until late 20th century focused heavily on blockbuster molecules than
drug product development. All stages of the product development involved rigorous
experimentation by One-Factor-At-a-Time (OFAT) approach. It involved varying one component
at a time and observe resulting changes in the outcome. OFAT approach is therefore time
consuming, tedious, and expensive. Quality by design (QbD) overcomes these limitations.
1400

Publications
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Figure 1-4. The number of publications with the keywords “design of experiments” and
“pharmaceutical” from 1950 through 2020, indicative of the scientific efforts being put in the field
(assessed from PubMed and Scopus databases on December 01, 2020)
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QbD is currently encouraged by FDA and other regulatory agencies towards the development
of new drug products as well as the generic products.69, 70 A comprehensive search in PubMed and
Scopus databases for the keywords “design of experiments” and “pharmaceutical” (Figure 1-4)
revealed an exponential increase in publications during the last two decades. This is evident from
only about two publications in 1970’s and more than 200 publications in 2010. Since 1950, more
than 12000 publications in PubMed and more than 6200 publications in Scopus were observed.
Numerous smart experimental designs are available to deliberately screen, optimize, and
validate various stages of drug product development. However, their application is not universal
and vary with formulation and processing method. Table 1-4 summarizes a list of polymeric
microparticle and nanoparticle formulations using DoE approaches.
Types of DoE
The International Council for Harmonization (ICH)70 defined DoE as “A structured, organized
method for determining the relationship between factors affecting a process and the output of that
process”. It is a set of predefined experimental trails designed to elucidate the effect of independent
variables under controlled conditions that are hypothesized to reflect the variation in quality of a
final product. Figure 1-5 illustrate eight distinct rules to thoroughly plan and execute DoE.
Make
conclusions

Observe a
phenomenon

Analyze
data

State a
problem/objective

Rule of ‘8’ to
execute Design
of Experiments
List all possible
variables

Collect data

Setup
experi
mental
design

Define
hypothesis

Figure 1-5. Eight distinct rules to design and execute pharmaceutical product development by
design of experiments approach
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Selected dependent variables in the design are evaluated by a summary of fit and analysis of
variance (ANOVA). The summary of fit includes the coefficient of determination (R2) and adjusted
R2. The R2 represents the fraction of deviation in the response that can be ascribed to the model
instead of random error. The adjusted R2 is used to compare model fitness when a different number
of parameters are used.15 An R2 closer to 1 indicates a relatively better predictor of the response
than its mean. ANOVA provides parameters to compare the fitted model with predicted values and
is used to identify individual factors and their interactions showing significant impact on response
variables.

Figure 1-6. Broad schematic illustrating the execution of design of experiments with knowledge
space, design space, target space, and control space
The choice of an experimental design depends mainly on the study objectives and the number
of factors to be investigated (Figure 1-6). Numerous statistical software packages like JMP ® (SAS
Institute, Cary, NC), Design-Expert® (Stat-Ease Inc., Minneapolis, MN), and Minitab® (Minitab
LLC, State College, PA) are widely used across the globe to execute DoE. These packages do not
require computer coding skill set unlike other recognizable statistics packages such as The R
Project and MATLAB®. Of the experimental designs reported in the literature, Plackett-Burman
designs, factorial designs, mixture designs, and response surface designs are widely explored in
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pharmaceutical development.63 The goodness of a design is measured by ‘design efficiency’. It is
a diagnostic tool that is relative to a hypothetical orthogonal design. Design efficiency values are
not useful as absolute measures but can be used in relative fashion to compare one design to the
other.
Plackett-Burman designs and mixture designs are usually used to screen appropriate ‘design
space’ and identify high-risk factors for further experimentation. Factorial designs are used in both
screening as well as optimization studies. Response surface designs are widely used during process
optimization studies. These designs are widely used to extract correlation between the high-risk
independent variables and the dependent variables to define a ‘control space’.
Plackett-Burman designs are used for screening experiments where main effects are confounded
with two-factor interactions.71 These design are cost-effective and useful in evaluating the impact
of large main effects with few experiments, assuming all interactions are negligible when
compared with main effects.

Figure 1-7. Main types of experimental designs: [A] factorial design; [B] mixture design; [C]
central composite design; and [D] Box-Behnken design
Factorial design71 (Figure 1-7[A]) is a research methodology that allows investigation of the
main and interaction effects between two or more independent factors on one or more dependent
variables. They are typically used in early stages of process development. Factors can be adjusted
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independently in the factorial designs. The number of experiments in the factorial design increases
exponentially with increase in the number of independent variables or factors. Based on the
resolution, the factorial designs are categorized to two types: (i) full factorial design, and (ii)
fractional factorial design.
Full factorial design is a design in which every “every setting of every factor appears with
every setting of every other factor”.71 The number of runs in a full factorial design is calculated by
‘Lk’, where the base ‘L’ represents the number of levels per factor and the exponent ‘k’ represents
number of factors. For example, a five-factor experiment with two levels per factor results in 32
(25) experiments.
Fractional factorial design involves experiments with a selected fraction/subset of the
experiments from a full factorial design. These designs are mainly used to make experiments
cheaper and quickly investigate cause-and-effect relationship of significance in a defined design
space. The number of runs in a fractional factorial design is calculated by ‘L k-p’, where the base
‘L’ represents the number of levels per factor, ‘k’ represents number of factors, and ‘p’ represents
number of confounded interactions that cannot be estimated independently. For example, a fivefactor experiment with two levels per factor and one confounded interaction results in 16 runs (2 51).

The design in this case is ½ of a full factorial design with five-factors and two levels per factor.
Mixture designs (Figure 1-7[B]) are typically used to explain the scope of each component and

its proportion in the formulation.63 They are usually applied during formulation development when
the overall composition of a formulation is defined. Unlike factorial design, parameters cannot be
adjusted independently in the mixture designs. Therefore, it is understandable that the factors in a
mixture design are dependent to each other. A decrease in proportion of one factor increases the
proportion of one or more of the remaining factors in the design. Mixture designs are rarely used
to investigate the interactions between formulation and process variables.
Response surface designs71 such as central composite design (Figure 1-7[C]) and BoxBehnken design (Figure 1-7[D]) are widely used during process optimization studies. Central
composite design is a factorial design embedded with center points that is augmented with a group
of ‘axial points’. These ‘axial points’ allow the estimation of curvature.71 Box-Behnken design
does not contain a factorial design embedded with center points. It is an independent quadratic
design that is rotatable and requires minimum three-levels of each factor. Central composite
designs have more capability for orthogonal blocking compared to Box-Behnken design.71
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Table 1-4. Examples of Design of Experiments application in polymeric microparticles and
nanoparticles formulation development
Formulation
Multivariat Manufacturing process
Factors
e models
Ipratropium
• 27-3 FFD Spray drying
• Independent variables:
bromide
lactose %; L-leucine %;
• Custom
15
microparticles
ethanol %; spray gas
RSD
pressure (mm); aspiration
%; feed rate (%); inlet
temperature (°C)
• Dependent variables:
product yield %; size;
span; and outlet
temperature (°C)
L-arginine
• Custom
• Air-jet milling
• Independent variables:
microparticles72
design
manufacturing process type
• Ball milling
• PCA
• Dependent variables: size,
• Spray drying
densities, Hausner ratio;
Carr’s index; cohesion;
moisture uptake; fine
particle fraction; fine
particle dose
Micronized
Air-jet milling
• CCD
• Independent variables:
ibuprofen and
grinding nozzle pressure;
indomethacin73
pushing nozzle pressure
• Dependent variables:
product yield %; size; span
VerapamilDouble emulsion solvent • Independent variables:
• FD
loaded
evaporation
aqueous phase pH;
®
Eudragit RS
polymer concentration;
100
API amount
74
microparticles
• Dependent variables:
product yield %; size;
EE%; API release at 2 h
CilnidipineSolvent
evaporation
• PBD
• Independent variables:
loaded PLGA
(emulsification followed
polymer amount; surfactant
• CCD
nanoparticles75
by ultrasonication)
concentration;
homogenization speed;
homogenization time;
ultrasonication time;
sonication amplitude;
sonication temperature
• Dependent variables: size,
EE%
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Cucurbitacin Bloaded DSPCPLGA hybrid
nanoparticles76

•

FD

One-step self-assembly
by sonication

•

•
Berberineloaded PCL
nanoparticles77

•

FD

Nanoprecipitation

•
•

Doxorubicinloaded PLGA
nanoparticles78

•

BBD

Solvent evaporation
(emulsification followed
by ultrasonication)

•

•
Dexamethasone
-loaded PLGA
nanoparticles79

•

FD

Solvent
displacement/evaporatio
n

•

•
Telmisartanloaded PLGA
nanoparticles80

•
•

PBD
BBD

Double emulsion solvent
evaporation

•

•
Pioglitazoneloaded PCL
nanopariticles81

•

FD

Nanoprecipitation

•

•
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Independent variables:
PEG conjugated
phospholipid/biodegradabl
e polymer ratio; total
lipids/lecithin molar
percentage ratio
Dependent variables: size;
span; surface charge
Independent variables:
drug to polymer ratio;
surfactant concentration
Dependent variables: size;
span; EE%
Independent variables:
PLGA concentration;
sonication time; oil to
water ratio; PVA
concentration
Dependent variables: size;
span; surface charge; EE%
Independent variables:
dexamethasone
concentration; PLGA
concentration; sodium
taurocholate concentration
Dependent variables: size;
span; surface charge; EE%
Independent variables:
PLGA concentration; PVA
concentration;
homogenization speed
Dependent variables: size;
surface charge; EE%
Independent variables:
solvent to anti-solvent
ratio; polymer
concentration; surfactant
concentration
Dependent variables:
product yield %; size;
span; surface charge; EE%;
API release

Enoxaparinloaded
Eudragit® FS
30D and RS-PO
microparticles82

•

CCD

Double emulsion solvent
evaporation

•

•
siRNA-loaded
lipidoid-PLGA
hybrid
nanoparticles83

•
•

Budesonideloaded DOTAPPLGA hybrid
nanoparticles84

•

Curcuminloaded
Eudragit® FSPCL
microparticles85

•

Gefitinib-loaded
Eudragit®
RL100
nanoparticles86

•

OFAT
FFD

Double emulsion solvent
evaporation

•
•

Custom
RSD

Double emulsion solvent
evaporation

CCD

Emulsification followed
by solvent evaporation

•
•

•

•

FD

Solvent evaporation
(emulsification followed
by ultrasonication)

•

•

19

Independent variables:
Eudragit® FS30D/Eudragit® RS-PO
ratio; PVA concentration;
sodium chloride
concentration
Dependent variables: size;
EE%; API release
Independent variables:
lipidoid content; lipidoid to
siRNA weight ratio
Dependent variables: size;
span; surface charge; EE%;
siRNA loading efficiency;
transfection efficiency; cell
cytotoxicity
Independent variables: API
content; lipid content
Dependent variables: size;
span; surface charge; API
EE%; lipid EE%; API
loading efficiency
Independent variables:
curcumin concentration;
Eudragit® FS proportion;
Eudragit® FS to PCL ratio
Dependent variables:
product yield %; size;
span; API EE%; API
loading efficiency; API
release
Independent variables:
PVP K30 concentration
PVA concentration;
sonication time
Dependent variables: size;
span; surface charge

Satranidazoleloaded PLGA or
Eudragit® S100
nanoparticles87

•
•

PBD
FD

Nanoprecipitation

•

•

Telmisartanloaded
poloxamer 407
nanoparticles88

•

BBD

Microchannel
precipitation

•

•
Diclofenacloaded gelatin
nanoparticles56

•
•
•

OFAT
CCD
FFANN

•
•

Nanoprecipitation
Two-step desolvation

•

•
Linezolidloaded
mannosylated
gelatin
nanoparticles89

•
•

Methotrexateloaded gelatin
nanoparticles90

•

Diclofenacloaded gelatin
microspheres91

BBD
TOA

Two-step desolvation

•

•

•
•

BBD

PBD
CCD

Two-step desolvation

•

Emulsion-crosslinking

•
•

•
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Independent variables: API
amount; polymer type;
polymer amount; stabilizer
type; stabilizer amount;
aqueous phase volume;
stirring time; stirring speed
Dependent variables: size;
span; surface charge; EE%;
API release
Independent variables:
polymer to API ratio;
solvent flow rate;
microchannel length
Dependent variables: EE%;
API release
Independent variables:
desolvating agent type;
gelatin type; gelatin bloom;
stabilizer concentration;
polymer amount;
crosslinker concentration
Dependent variables: size;
surface charge; EE%
Independent variables:
polymer amount;
crosslinker concentration;
temperature
Dependent variables: size;
span; EE%
Independent variables:
stirring speed; crosslinking
time; crosslinker
concentration
Dependent variables: size
Independent variables:
gelatin type; gelatin bloom;
surfactant type; surfactant
amount; oil phase type; oil
phase amount; emulsion
speed; emulsion time;
crosslinker concentration
Dependent variables: size
distribution; drug loading

API: active pharmaceutical ingredient; BBD: Box-Behnken design; CCD: central composite
design; DSPE: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine; EE: entrapment efficiency;
FD: full factorial design; FFD: fractional factorial design; FF-ANN: feed-forward artificial
neural network; GMO: glyceryl monooleate; OFAT: one-factor-at-a-time; PCA: principal
component analysis; PBD: Plackett-Burman design; PCL: poly(-caprolactone); PLGA:
poly(lactide-co-glycolide); PVP: polyvinyl pyrrolidone; PVA: polyvinyl alcohol; siRNA: small
interfering ribonucleic acid; TOA: Taguchi orthogonal array design
1.5.Strategic Statistical Modeling in Polymeric Particle Engineering for Drug Delivery
One of the primary objectives of particle engineering is to first gather quantitative data that can
help guide improvement efforts for therapeutics during the lifecycle of a drug product. Application
of advanced particle engineering technologies in polymeric drug delivery systems has shown to
improve the efficacy of a drug substance by maintaining stable levels in the blood when compared
to traditional parenteral drug products. These technologies facilitate launching of novel
therapeutics with adapted delivery platforms, offer superior treatment performance, and prolong
pharmaceutical products lifecycle through innovative delivery systems. However, formulation and
manufacturing of these advanced pharmaceutical particulate products is a complex multifaceted
process. Challenges associated with formulation composition, material lot-to-lot/grade-tograde/vendor-to-vendor variability, process parameters, scalability etc., have to be addressed at the
initial stages of development to avoid product failures. Therefore, formulation development
scientists need to comprehend and control a range of unit manufacturing operations along with the
formulation composition for a successful product.
The overall objective of this research project was to explore experimental design strategies and
applications in formulating microscale and nanoscale polymeric particles for drug delivery.
Numerous smart experimental designs such as factorial design, central composite design, mixture
design etc., are available to deliberately screen, optimize, and validate various stages of drug
product development. However, their application is not universal and vary with formulation. This
may in part be due to different types of delivery systems and formulation techniques. The
introduction of quality by design guidance by regulatory agencies69 has given opportunity for
pharmaceutical community to cover the underlying science in materials and processes, at-thesame-time confounding researchers from completely understanding these complex entities.
Questions such as— How do two models differ in prediction? When do we completely
understand the impact of a material or/and a process? What type of experimental design or tool is
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appropriate to better understand them?—were although satisfactorily answered for conventional
drug products92, they are not well addressed for advanced delivery systems (example, micro- and
nano- carriers). Several formulation development studies driven by the design of experiment or
multivariate analysis (MVA) tools were reported in literature15, 93, 94, but inscrutable reproducibility
issues often tagged them. We believe this might be due to specificity of a statistical tool, process,
technique, or material used in the study. Therefore, we identified the need to compare the
computational ability of various statistical tools in the development of an advanced microscale and
nanoscale drug products with minimum number of experiments.
Specific aims include—
1. Engineer polymeric microparticles using multivariate analytical tools with minimum
experiments
a. Formulate microsponge particles using traditional coacervation phase separation technique
i. Model responses by multiple linear and principal component regressions
ii. Compare predictability of multiple linear and principal component regressions models
b. Formulate inhalable microparticles using spray-drying and spray freeze-drying technique
i. Model responses by multiple linear regression
ii. Identify lead formulations and compare aerosolization characteristics
2. Engineer polymeric nanoparticles using multivariate analytical tools with minimum
experiments
a. Design controlled unit operations to formulate gelatin nanoparticles using desolvation
technique
b. Characterize physical properties of various gelatin grades
c. Identify critical variables that impacts the physical attributes of gelatin nanoparticles
d. Investigate strategies to mitigate gelatin grade-to-grade variability and engineer gelatin
nanoparticles with reproducible physical properties using desolvation process
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Chapter 2 : COMPUTATIONAL PREDICTABILITY OF MICROSPONGE
PROPERTIES USING MULTIPLE LINEAR AND PRINCIPAL COMPONENT
REGRESSION MODEL
Abstract
The capabilities of principal component regression (PCR) and multiple linear regression
(MLR) were evaluated to decipher and predict the impact of formulation and process parameters
on the modeled metronidazole benzoate (MB)–ethyl cellulose (EC) microsponge (MBECM)
properties. MBECM were prepared by a quasi-emulsion solvent diffusion method. A minimum
experimentation was designed using Box-Behnken approach with one center point after initial
screening experiments. Data was modeled by principal component analysis (PCA), PCR, and
MLR. Two distinct groupings of developed MBECM was observed in initial qualitative PCA as a
function of their respective formulation and processing parameters. Group A formulations with
low dichloromethane, high PVA, and low stirring speed exhibited larger particle size, lower
entrapment efficiency (EE), and lower actual drug content (ADC) than Group B formulations.
Optimized quantitative PCR and MLR models demonstrated a linear dependence of particle size
and quadratic dependence of EE and ADC on the studied formulation and process parameters.
Interestingly, MLR models showed relatively better predictability of the selected MBECM
formulation properties when compared with PCR. Thus, a properly designed minimum
experimentation coupled with multivariate modeling generated a knowledge-rich target space,
which enabled to understand and predict the performance of developed MBECM within a
prescribed design space.
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2.1.Introduction
Advanced strategic solutions are imperative to accelerate drug development processes as per
ICH Q8 guidelines.69 A smart experimentation and data management are one of the cogs of such
advanced strategic solutions. Previous conservative approach of pharmaceutical companies such
as “file first and figure it out later” toward regulatory framework led to testing the quality of a
finished drug product, rather than developing the “in-build” quality products. This has confined
the development of several small molecules and biopharmaceutical products from instigating
innovative methodologies for many years.
However, a successful pharmaceutical product development is an outcome of the identified
critical quality attributes of material and process parameters influencing the properties of a final
drug product in the early development stages. This approach eventually provides a safe, economic,
and an efficacious medication to patients. Such initial detailed investment in the lab scale could
help for a successful translation to pilot, and then to commercial scales, which can facilitate a real
time control and continuous manufacturing of the pharmaceuticals. Thus, a well-thought
experimentation and understanding of the findings during early research stages are extremely
critical to minimize risks at later scale-up. Such operational excellence based on real-time control
and continuous manufacturing approach enabled Amgen pharmaceuticals to break two (20,700
defects occur per million opportunities) to three sigma (2,700 defects occur per million
opportunities) barriers to reach six-sigma (3.4 defects occur per million opportunities) at their
every manufacturing facility. This has helped Amgen to save over $300 million annually.95
Evidently, exploring new horizons for an effective as well as efficient product development is
highly beneficial for both manufacturers and patients.
Numerous smart experimental designs such as factorial design, central composite design,
mixture design etc., are available to deliberately screen, optimize, and validate various stages of
drug product development. However, their application is not universal and vary with formulation.
This may in part be due to different types of delivery systems and formulation techniques. The
introduction of quality by design guidance by regulatory agencies69 has given opportunity for
pharmaceutical community to cover the underlying science in materials and processes, at-thesame-time confounding researchers from completely understanding these complex entities.
Questions such as—When do we completely understand the impact of a material or/and a process?
What type of experimental design or tool is appropriate to better understand them? How do two
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models differ in prediction?—were although satisfactorily answered for conventional drug
products92, they are not well addressed for advanced delivery systems (example, micro- and nanocarriers). Several formulation development studies driven by the design of experiment or
multivariate analysis (MVA) tools were reported in literature15, 93, 94, but inscrutable reproducibility
issues often tagged them. We believe this might be due to specificity of a statistical tool, process,
technique, or material used in the study. Rakić et al. compared four experimental design types in
high pressure liquid chromatographic method development and demonstrated the importance of
understanding experimental design methodology to uncover complex system behavior and optimal
conditions.96 To authors knowledge, no such studies were reported in advanced pharmaceutical
drug product development. Therefore, we identified the need to compare the computational ability
of two statistical tools in the development of an advanced drug product with minimum number of
experiments.
We hypothesize that there is no difference in predictability between MLR and PCR models
in the development of advanced drug products with minimum experiments. Microsponge product
development by a quasi-emulsion solvent diffusion97, a well-explored platform for extended
release of the API, was chosen for this study. Metronidazole benzoate (MB) was selected as a drug
of choice for periodontitis indication.98 Ethyl cellulose (EC) was used as a polymer in the
development of microsponges due to its mucoadhesive properties. We believe the strategy of using
minimum experimentation coupled with multivariate modeling will generate and predict the
performance of MB–EC microsponge (MBECM) within a preferred design space. Furthermore, a
thorough understanding of computation models will enable to decode underlying pros and cons
while attempting to resolve any existing limitations and expedite research work stream.
2.2.Materials
MB and EC were obtained as gift samples from Aarti Drugs Ltd. (Mumbai, India) and
Colorcon® Asia Pvt. Ltd. (Mumbai, India), respectively. All other chemicals and solvents were of
analytical grade (Research Lab Fine Chem Industries, Mumbai).
2.3.Methods
2.3.1. MBECM preparation
A desired amount of EC polymer was first dissolved in 10 mL dichloromethane (DCM)
followed by MB, using sonication at ~35°C for 15 min for initial screening experiments (Figure
2-1). This MB-EC drug-polymer solution was used as an internal phase. The external phase was
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100 mL distilled water with 500.00 mg of PVA as emulsifier. The internal phase consisting drugpolymer solution was finely dispersed in external phase and allowed to mix in ambient conditions
for 60 min to form a quasi-emulsion.
Required amounts of DCM and PVA were taken for the preparation of respective internal and
external phases for Box-Behnken design (Table 2-1). The internal phase was added to the external
phase and allowed to mix at controlled stirring (Table 2-1) for 60 min under ambient conditions.
DCM diffuses from the finely dispersed drug-polymer droplets due to its high escaping tendency
leading to the solidification of drug-polymer matrix. This hydrophobic drug-polymer matrix
separated out from aqueous external phase was filtered through Whatman ® filter paper (2.5 μm,
Grade 5, GE Healthcare), and the recovered MBECM were dried in hot air oven at about 40°C for
approximately 30 min.
2.3.2. Experimental design and MVA
A two-phase approach was followed to study the impact of material and process parameters
with minimal experimentation. Five different drug/polymer ratios (Figure 2-1) were investigated
in phase I to screen the composition with desired particle size, entrapment efficiency (EE), and
actual drug content (ADC). A two-level Box-Behnken design with one center point was applied in
phase II to understand the impact of “practically possible extreme” limits (upper and lower) of
design variables with a minimum number of experiments.96 Additionally, this design separates out
the impact of main effects and quadratic effects on the measured microsponge properties. The
drug/polymer ratio locked from phase I screening experiments and the total quasi-emulsion
volume (100 mL) were kept constant throughout the trail runs. The parameters PVA amount,
stirring speed, and DCM were evaluated at three levels to generate the design (Table 2-1) for
particle size, EE, and ADC. JMP® v14 statistical software (SAS Institute Inc., Cary, NC) was used
to design the experiments and analyze data for multiple linear regression (MLR) modeling. This
modeling assists to interpret the relationship between two or more explanatory variables and
response variables by fitting an equation to obtained data.
Principal component analysis (PCA) and principal component regression (PCR) models were
generated using Unscrambler ® v10 software (CAMO Software AS, Trondheim, Norway). PCA
decodes hidden data patterns while PCR quantifies the influence formulation and process
parameters on subsequent response variables.93 The design and response variables were weighted

26

and scaled by dividing with their standard deviation before each modeling. The uncertainty of PCR
coefficient was estimated with full cross-validation and Jack-Knifing method.99
2.3.3. Physicochemical characterization of MBECM
2.3.3.1.

Particle size

The average particle size (d50) was measured using Labomed LX 300 Binocular microscope
(Lablink Instruments, Hyderabad, India) connected with Pixel Pro® software. The microscope and
software were calibrated using a stage micrometer prior to analysis. Samples were focused imaged
under the calibrated microscope. The size of MBECM was measured from annotation mode of the
software. About 200 MBECM particles were measured to report d50 value.
2.3.3.2.

EE and ADC of MBECM

Accurately weighed samples of MBECM were dissolved in 190 proof ethanol (~75 mL) under
sonication for an hour. The samples were filtered and MB content in the filtrate was measured
using ultraviolet (UV) spectrophotometer (UV-1700 series, Shimadzu Corporation, Kyoto, Japan)
at λmax of 277 nm.100 A calibration curve based on standard solutions of MB in 190 proof ethanol
was used to estimate MB content in respective MBECM formulations. The ADC and EE were
calculated using Eqs. (1) and (2), respectively.
𝐴𝐷𝐶 (%) =

EE (%) =

𝑀𝑎𝑐𝑡𝑢𝑎𝑙
𝑀𝑚𝑖𝑐𝑟𝑜𝑠𝑝𝑜𝑛𝑔𝑒
Mactual

Mtheoretical

× 100

(1)

× 100

(2)

where, Mactual is the actual MB content in weighed quantity of MBECM, Mmicrosponge is the weighed
quantity of MBECM, and Mtheoretical is the theoretical amount of MB used in the MBECM
formulation.
2.4.Results and Discussion
2.4.1. One-factor-at-a-time analysis
Initial screening studies with five experiments were performed to evaluate the impact of
drug/polymer ratio on MBECM particle size, EE, and ADC. Smaller particle size with maximum
EE and ADC are desired characteristics in the final product.
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Figure 2-1. Preliminary screening experiments of five formulations to identify desired
metronidazole benzoate (MB) and ethyl cellulose (EC) ratio in microsponge based on desired
entrapment efficiency (EE %), mean particle size (PS µm), and actual drug content (ADC %).
Various drug: polymer ratios used were– 2.0:1.0 (66.66% MB); 1.5:1.0 (60.00% MB); 1.0:1.0
(50.00% MB); 1.0:1.5 (40% MB); and 1.0:2.0 (33.33% MB).
Table 2-1. Box-Behnken design for optimizing Metronidazole benzoate-ethyl cellulose
microsponges
Formulation
PVA
Stirring
DCM
EE (%)
Particle size
ADC
code
(mg)
speed (rpm)
(mL)
(µm)
(%)
F1
500
1500
10
72.00
27.40
50.65
F2
400
1200
10
78.28
24.52
67.23
F3
500
1200
15
77.15
12.75
66.53
F4
500
1200
5
61.07
42.63
41.77
F5
600
1200
10
78.22
32.08
59.44
F6
400
1500
5
68.25
37.39
65.54
F7
400
1500
15
83.42
7.40
77.48
F8
600
1500
5
75.87
48.89
67.56
F9
600
1800
10
85.87
14.30
86.73
F10
400
1800
10
86.44
13.33
74.74
F11
500
1800
5
77.52
20.34
71.09
F12
500
1800
15
76.60
14.44
74.62
F13
600
1500
15
79.78
17.63
82.72
n=1
ADC, actual drug content; DCM, dichloromethane; EE, entrapment efficiency PVA, polyvinyl
alcohol
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The MBECM formulation having a drug/ polymer ratio of 1.5:1.0 showed a mean particle size
of 20.62 μm, 70.86% EE, and 66.34% ADC, compared with other formulations (Figure 2-1). This
drug/polymer ratio was chosen to further investigate the impact of formulation (PVA and DCM
amounts) as well as process variables (stirring speed) on the MBECM properties with BoxBehnken design and generate data for developing various multivariate predictive models. The
theoretical and actual strengths of MB in this chosen phase I screening design formulation were
20.00% w/w and 13.27% w/w, respectively.

Figure 2-2. Principal component analysis [A] score plot and [B] loadings plot of metronidazole
benzoate—ethyl cellulose microsponges prepared as per Box-Behnken design. Displayed first two
principal components explained 73.1% variance in the data. ADC- actual drug content; DCMdichloromethane; EE- entrapment efficiency; PVA- polyvinyl alcohol.
2.4.2. Principal component analysis
The preliminary qualitative correlation between formulation parameters, process parameter,
and response variables of all the trials from Box-Behnken design (Table 2-1) was probed with
PCA (Figure 2-2). The PCA score plot (Figure 2-2A) distinguishes the sample pattern, grouping
similarities and differences within a multidimensional data set. The PCA loadings plot (Figure 22B) reveals the variables responsible for the sample pattern, grouping similarities and differences
in the PCA score plot. Thus, a simultaneous interpretation of both score and loading plots is
necessary. The samples and variables located on the same principal component (PC) axis have
positive correlations, while those located on opposite side of PC axis have negative correlations.93
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The present study utilized five PCs to explain 100% variance in the data, while first two PCs
explained about 73.1% variance in the data. The PCA score plot (Figure 2-2A) showed two distinct
groupings along PC1 axis. Group A formulations located on the negative side of PC1 axis is
composed of F1, F2, F4, F5, F6, and F8. Group B formulations consisting F3, F7, F9, F10, F11,
F12, and F13 are located on the positive side of PC1 axis. Their distribution on the either side of
PC axis indicated that Group A formulations have different properties than Group B formulations
as a function of formulation parameters, process parameters, and resulting responses. Group A
formulations in score plot (Figure 2-2A) and PVA as well as mean particle size in loading plot
(Figure 2-2B) are on the same side of PC1 axis, and therefore are directly correlated. This indicates
that MBECM formulations produced with a high PVA concentration resulted in large particle. As
emulsifying agent, PVA is expected to reduce the mean particle size with increase in the
concentration up to a critical concentration.101 However, addition of PVA beyond the critical
concentration leads to increase in the particle size of microsponges. This was attributed to increase
in the viscosity of aqueous medium with a higher amount of emulsifier. Such enhanced viscosity
of aqueous medium can discourage the initial breakdown of the disperse phase into smaller
globules that can cause the formation of large sized microsponge formulations.101, 102 Additionally,
this phenomenon can reduce the EE and ADC of microsponges.95 Furthermore, Group A
microsponges exhibited lower EE (61% to 78%) and ADC (41% to 68%). On the other hand,
Group B microsponges formulations, stirring speed, DCM content, ADC, and EE are on the same
side of PC1 axis (Fig. 2), indicating their direct correlation to one another. Group B MBECM
formulations produced with a higher amount of DCM and high stirring speed seems to have a
smaller mean particle size than Group A formulations. These formulations also have a higher EE
(77% to 86%) and ADC (67% to 87%) than Group A formulations. The established
relationships between stirring speed, volume of internal phase and microsponge particle size is
consistent with previous findings in the literature.101, 103, 104
2.4.3. Principal component regression
The qualitative relationships between formulation components, process parameters, and
response variables of MBECM decoded with PCA was further quantified with PCR to develop
predictive models (Figures 2-3 to 2.5). Quantitative impact of main effects, square effects, and
interactions of stirring speed, DCM content, PVA content (X-variables) on the individual Yvariables such as mean particle size (Figure 2-3), EE (Figure 2-4), and ADC (Figure 2-5) were
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examined with the optimized PCR model. The statistical significance of the studied X-variables
on Y-variables was represented with 95% confidence interval bars. The variables with 95%
confidence interval bars crossing the zero line are considered as statistically insignificant. For
significant variables, the sign and magnitude of the coefficient bar indicate their impact on the Yvariables.

Figure 2-3. Weighted principal component regression coefficients of metronidazole benzoate—
ethyl cellulose microsponges particle size

Figure 2-4. Weighted principal component regression coefficients of metronidazole benzoate—
ethyl cellulose microsponges entrapment efficiency (%)

Figure 2-5. Weighted principal component regression coefficients of metronidazole benzoate—
ethyl cellulose microsponges actual drug content (%)
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The main, interactions, and square effects for statistically insignificant variables were taken
out from the model until it leads to improvement in the model accuracy. The accuracy of the model
was measured with an improvement in R2 values and root mean square values at calibration and
validation stages. The statistical significance of the models were determined at p<0.05.105 Positive
regression coefficients indicate a positive effect on the Y-variables and vice versa.
The optimized mean particle size PCR model is shown in Figure 2-3. The linear regression
equation of a mean particle size PCR model is given in Eq. 3. The root-mean-square error (RMSE)
at the calibration and the prediction stages were 4.55 µm and 7.49 µm, respectively. The model
regression coefficients at the calibration stage and the prediction stages were 0.8629 and 0.6840,
respectively.
Mean particle size (μm) = 63.83 + 0.04(PVA) − 0.02(Stirring speed) − 2.42(DCM)

(3)

This model showed a statistically significant positive impact of PVA and negative impacts of
stirring speed and DCM on the mean particle size of developed MBECM. As mentioned earlier, a
positive impact of PVA on the particle size can be explained with difficulty in breaking down the
disperse phase into smaller particles due to increased viscosity of an aqueous medium, after
addition of PVA above its critical concentration.101, 102 The negative impact of stirring rate might
be due to a high shearing energy associated with high stirring rate. This high shearing energy
provided by a high stirring speed breaks the internal organic phase particles into smaller particles,
and also narrows the size distribution.103 The negative impact of DCM on particle size might be
attributed to the reduction in the viscosity of an internal organic phase due to high DCM volume.
Such low viscosity might offer less resistance for the stirring induced breaking of internal phase
into smaller particles.103
The linear regression equation of EE PCR model is given in Eq. 4 and Figure 2-4. The RMSE
at the calibration and the prediction stages were 2.70% and 4.40%, respectively. The model
regression coefficients at the calibration stage and the prediction stages were 0.8350 and 0.6274,
respectively.
EE (%) = 42.34 + 0.01(Stirring speed) + 0.86(DCM)
− 2.83[(Stirring speed)(DCM)] + 4.43(PVA)2

(4)

The main effects of stirring speed and DCM levels showed statistically significant positive
impacts on the EE of developed microsponges. In addition to these main effects, interactions
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between stirring speed and DCM levels showed significantly negative impact, while square effects
of PVA showed significantly positive impact on the EE.
Generally, it was observed that a high stirring speed leads to reduction in the loading efficiency
as a function of reduced globule size of internal phase. This phenomenon leads to enhanced
partitioning of drug into aqueous dispersion medium. Majority of these studies incorporated watersoluble drug.106, 107 However, in the present investigation stirring speed seems to encourage the
encapsulation of hydrophobic MB in the microsponges. As mentioned previously, increased
stirring speed during the emulsification process produces smaller sized globules of the internal
phase. This provides a larger surface area to the particles and encourages a more direct contact
between internal organic phase and external aqueous phase106, favoring better solvent diffusion of
water miscible DCM into external aqueous phase. Additionally, reduced globule size could also
speed up the removal rate of diffused DCM having lowest heat of evaporation from water/air
interface by evaporation.108 This can ultimately leave a hydrophobic drug rich polymer matrix,
which can undergo subsequent phase separation from the external aqueous phase.
A positive impact of DCM on the EE suggests that a higher volume of internal organic phase
favoring a drug rich polymer matrix. This can be attributed to the increased polymer–solvent
interactions in the presence of higher DCM volume. Such enhanced interactions could expand the
polymer chain, which might reduce drug diffusion and subsequent drug loss to the aqueous
phase.108
Interestingly, a negative impact of interactions between the stirring speed and DCM indicates
a positive or negative “conditional impact” of the main variables. A positive interaction effect
denotes synergistic effect of the two variables. In other words, a positive effect of Variable 1 can
encourage a more positive impact of Variable 2. Alternatively, a negative interaction effect
represents an antagonistic effect of the two variables. Such antagonism insinuates that a more
positive impact of Variable 1 can cause a more negative impact of Variable 2.105 It seems that low
stirring speed and high DCM volume could lead to microsponges with a lower EE, which might
be due to a larger particle formation. Diffusion of such large particles might be hampered due to
reduced contact between internal organic phase and external aqueous phase.
A square effect of PVA showed a positive impact on the EE. This quadratic effect might be
speculated as a reduced interfacial tension between organic phase and aqueous phase regardless of
increased viscosity of internal aqueous phase after addition of PVA above the critical
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concentration. This can enhance the diffusion of organic phase into aqueous phase and subsequent
evaporation of DCM from the from water/air interface.
The ADC linear regression equation and model plot are presented as Eq. 5 and Figure 2-5,
respectively. The RMSE at the calibration and the prediction stages were 4.11% and 7.11%,
respectively. The model regression coefficients at the calibration stage and the prediction stages
were 0.8615 and 0.6929, respectively.
ADC (%) = −5.21 + 0.01(PVA) + 0.03(Stirring speed) + 1.39(DCM)
+ 3.30[(Stirring speed)(PVA)] + 7.83(PVA)2

(5)

The main effects of PVA, stirring speed, and DCM showed statistically significant positive
impacts on the ADC of developed MBECM. As previously mentioned, stirring speed and DCM
exhibited positive impact on EE (Eq. 4). These parameters favored drug entrapment in the
developed MBECM and subsequently enhanced ADC. In addition, as stated previously, the
positive impact of individual as well as square effects of PVA on the ADC can be attributed to
enhanced organic phase diffusion due to reduced interfacial tension by PVA. Similarly, a positive
effect of interactions between stirring speed and PVA can be attributed to the enhanced diffusion
of the organic phase due to small globule formation under high stirring speed, coupled with a
reduced interfacial tension upon addition of PVA.
2.4.4. Multiple linear regression
The data obtained from the Box-Behnken experimental design was additionally modeled with
MLR using JMP® statistical software. This model assists to interpret the relationship between main
effects, interactions, and square effects of two or more design variables (X-variables) on the single
response variable (Y-variable) by fitting an equation to obtained data. All the critical individual
and two factor interactions along with nonlinear effects of the input parameters were investigated
by assessing the fit of linear and quadratic terms. Selected critical quality attributes—particle size,
EE, and ADC—were evaluated by summary of fit and analysis of variance (ANOVA). Model
fitness and intrinsic variation of a response variable will be explained by the summary of fit, using
R2, adjusted R2, and RMSE values. The R2 evaluates the proportion of variation in the response
that can be attributed to the model than to random error. The adjusted R2 is used to compare models
with different number of parameters, for better prediction, and the RMSE is used as an estimate of
standard deviation of the random error. ANOVA is used to identify independent factors showing
significant impact on response variables.
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Statistically significant models were determined for EE (p=0.0054; R2=0.9921; and adjusted
R2=0.9683) and ADC (p=0.0003; R2=0.9988; and adjusted R2=0.9952). ANOVA showed no
significant change between the particle size (p=0.0923; R2=0.9436; and adjusted R2=0.7743) of a
formulation. However, DCM was identified to show significant (p=0.0111) positive impact on
particle size, which could be due to high RMSE value. The RMSE of particle size, EE, and ADC
were 6.10 µm, 1.24%, and 0.86% respectively. Statistically significant predictive model equations
of each response variables (Eqs. 6-8), developed using MLR model, were derived by the best-fit
method excluding non-significant parameters (p>0.05). The values of each independent variable
in parentheses represent coded values. Each coded value is a difference between the actual values
from the center point, divided by the step value. The center point is the average of high and low
levels, whereas the step value is half the difference between high and low levels of the respective
independent variable.15
Particle size (μm) = 27.40 − 12.13(DCM)

(6)

EE (%) = 72.00 + 3.96(Stirring speed) + 4.28(DCM) − 2.82[(PVA)(DCM)]
− 4.25[(Stirring speed)(DCM)] + 6.97(PVA)2 + 3.23(Stirring speed)2

(7)

ADC (%) = 50.65 + 1.43(PVA) + 9.03(Stirring peed) + 6.92(DCM)
+ 4.95[(PVA)(Stirring speed)] − 5.31[(Stirring speed)(DCM)]
+ 15.60(PVA)2 + 5.78(Stirring speed)2 + 7.07(DCM)2

(8)

As expected, the model equations developed by PCR (Eqs. 3-5) and MLR (Eqs. 6-8) exhibited
common presence of various statistically significant impacts of several main variables,
interactions, and square effects on the response variables. These effects will not be discussed in
this section again. However, the statistically significant impacts of various effects different from
PCR model are discussed in this section. Curvature in EE (Figure 2-6B) and ADC (Figure 2-6C)
prediction profilers clearly depicts the dependence of these two response variables on the
interaction and crossover effects of formulation as well as process variables. The EE MLR model
showed negative impact of interactions between PVA and DCM amounts (p = 0.0198), while
positive impact of square effect of stirring speed (p = 0.0289). The negative impact of interactions
between PVA and DCM concentrations indicates that high PVA concentration above critical limit
and low DCM concentration might have increased the viscosity of external phase, which hinders
globule size reduction of internal phase. This might delay the internal phase diffusion and
subsequent precipitation of drug-polymer matrix. Such delay can lead to high partitioning of drug
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into aqueous dispersion phase steering to reduced EE. 101 On the other hand, an exponential positive
impact of stirring speed on EE can be attributed to the breakdown of internal organic phase to fine
globules and thereby enhancing the encapsulation of MB into MBECM.103 The ADC MLR model
showed a statistically significant negative impact of interactions between stirring speed and DCM
(p = 0.0011), along with positive effect due to square terms of stirring speed (p = 0.0020) and
DCM (p = 0.0011). We have difficulty to interpret the interaction effect between stirring speed
and DCM. However, positive square effects of stirring speed and DCM can be attributed due to
enhanced diffusion and drug-polymer interactions.

Figure 2-6. Response surface profilers of metronidazole benzoate–ethyl cellulose microsponges
formulations—[A] particle size, [B] entrapment efficiency (EE), and [C] actual drug content
(ADC)—as a function of stirring speed and polyvinyl alcohol (PVA)
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Figure 2-7. Prediction profiles of metronidazole benzoate–ethyl cellulose microsponges
formulations—particle size, entrapment efficiency (EE), and actual drug content (ADC)—as per
Box-Behnken design
Furthermore, a multi-criteria prediction profile plot (Figure 2-7) was used to identify the
optimum conditions of selected input variables in order to have smaller particle size, high EE, and
high ADC. It was found that a formulation prepared using 400 mg PVA, 15 mL DCM, and 1200
rpm stirring speed would give microsponges having particle size of 4.97 µm, EE of 86.90 %, and
ADC of 85.02 %.
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Figure 2-8. Comparison of measured and predicted values of metronidazole benzoate-ethyl
cellulose microsponge F9 formulation from optimized principal component regression (PCR) and
multiple linear regression (MLR) models. EE, entrapment efficiency; PS, particle size; ADC,
actual drug content.
2.4.5. PCR and MLR predictability
Finally, mathematical models generated from PCR and MLR were used to predict the
properties of MBECM F9 formulation, which was giving high ADC than rest of the formulations
(Table 2-1). An overlay of the measured and predicted values of particle size, EE, and ADC is
shown in Figure 2-8. Although the differences between measured and predicted values by PCR
and MLR models appear to be close (Figure 2-8), the MLR models showed relatively better
predictability than the PCR. The MLR models showed 18.88%, 0.70%, and 0.81% over-prediction
for particle size, EE, and ADC, respectively, when compared to their experimental values.
Whereas PCR models showed 2.33% under-prediction for EE while presenting 35.66% and 1.61%
over-prediction for particle size and ADC, respectively. Relatively larger deviations in the
predictability of PCR than MLR can be explained by the RMSE values of respective response
variables. The standard deviation of the random error in PCR were relatively larger than the MLR,
thereby increasing variability in the model. This indicates that the MLR models based on the
minimum Box-Behnken experimentation allowed both understanding and predicting the
formulation properties of the developed MBECM formulations. However, it would be interesting
to study the performance of optimized models using an independent validation data set.
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2.5.Conclusions
The predictive efficiencies of PCR and MLR multivariate methods were evaluated with the
data generated from a smart and minimal experimentation employed during the MBECM
production. The multivariate models established for particle size, EE, and ADC of MBECM
deciphered statistically significant influence of main, interactions, and square terms of the
formulation and process parameters. PCR and MLR methods showed that the mean particle size
was a function of main effects of investigated design variables. This suggests a linear dependence
of particle size on the stirring speed, PVA and DCM fractions. However, EE and ADC PCR and
MLR models showed dependence of these responses on the various main effects, interactions, and
square effects of design variables. It suggests their quadratic relationships with the studied design
variables. Although the differences between measured and predicted values by PCR and MLR
models appear to be similar, the MLR models showed relatively better predictability than the PCR.
However, it is important to test predictive performance of these optimized models on an
independent validation data set. Clearly, the developed minimum experimentation approach could
provide understanding and prediction of manufactured microsponge properties in a prescribed
design space.
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Chapter 3 : AEROSOLIZATION OF SILDENAFIL CITRATE LOADED POLYMRIC
MICROPARTICLES ENGINEERED BY SPRAY DRYING AND SPRAY FREEZEDRYING
Abstract
Dry powder inhaler (DPI) is an established patient-compliant pharmaceutical product for the
delivery of therapeutics. Aerosolization is the most critical quality attribute of the inhalable
polymeric microparticles engineered by spray drying (SD) and spray freeze-drying (SFD)
processes. A degree 3 extreme vertices mixture design was implemented to study the effect of
composition on SD process. A factorial design was implemented to study the effect of
microparticles composition on the physicochemical properties of the SFD product. Designated
response variables—yield%, size, span, and EE%— of SD and SFD were evaluated by summary
of fit and analysis of variance. SD produced small dense particles. SFD resulted in large light
particles. The results of the mass median aerodynamic diameter, geometric standard deviation, and
emitted dose recovery percent of both SD and SFD formulations were promising. This suggest that
the polymeric microparticles engineered by both SD and SFD demonstrate good aerosolization
properties. However, particles engineered by SD demonstrated relatively superior aerodynamic
characteristics than SFD.
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3.1.Introduction
Pulmonary drug delivery is a favorable administration route for quick onset of action and has
been a widely explored non-invasive alternative for the treatment of several respiratory and
systemic diseases.109, 110 The large alveolar surface area for absorption (24 – 180 m2 depending on
expiration and inspiration activities)111, extensive vascularization, absence of first pass
metabolism, and negligible proteolytic activity aids in quick onset action for a drug at low doses.
Recently, research has been directed toward the lungs as a new site for drug delivery and the
development of formulations for the treatment of pulmonary diseases and infections. 112 This idea
led to the development of pressurized metered dose inhalers (pMDIs) in the mid-1950s which
served as a lifeblood for the treatment of some of the chronic diseases like asthma and tuberculosis
(TB).113 Traditionally, chlorofluorocarbons (CFCs) were used as propellants. Due to
environmental safety issues, CFCs were abandoned, and the trend has shifted towards the use of
environmentally acceptable propellants, such as tetrafluoroethene and heptafluoropropane.
Nebulizers and pMDIs accounted for 90% of the inhalation formulations 114, but to their limitations
in drug loading, stability, and solubility, research interest was transferred towards dry powder
inhalers (DPIs).
DPIs deliver drugs into lungs in the form of microparticle aerosols. Morphology and
physicochemical properties of microparticles determine the fate of pharmacokinetics and
pharmacodynamics of a drug. Shape, size, and density determine the aerodynamic diameter of
microparticles, which serves as a parameter to determine the fate of drug deposition. Particles
having an aerodynamic diameter of greater than 5 µm get deposited on upper airway epithelia and
will be cleared quickly by mucociliary transport. Particles with an aerodynamic diameter between
1–5 µm get deposited in the tracheobronchial and bronco-alveolar region of the lungs. According
to Reinhard115, low density hollow particles having an aerodynamic particle size of 3±2 µm are
ideal for pulmonary drug delivery because they improve efficiency and quality of the drug product.
Various methods are available for production of microparticles, amongst which spray drying
(SD) is considered to be a favorable technique.114 It is a well-documented technique to formulate
various pulmonary drug delivery systems with optimum aerodynamic properties.116, 117 It is a
simple one-step process that can achieve efficient encapsulation of the drug within a polymer for
small and large-scale production. Spray dried particles are usually characterized by spherical
surface and suitable aerodynamic properties for controlled drug delivery to the lungs.118
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Spray freeze-drying (SFD) can be deemed as a hybrid technology, applying the principles of
SD and freeze-drying. This involves freezing of atomized droplets followed by solvent removal
by sublimation process through freeze-drying. The characteristics of a SFD products, upon
removal of water, are dependent not only on the formulation composition but also on the nature of
droplet formulation and freezing process.42 Unlike traditional lyophilization process, SFD
facilitates controls of particles size and distribution, which makes it a favorable process to engineer
polymeric microparticles for pulmonary delivery.
SD and SFD are not entirely new concepts. They have been widely explored powder
production techniques for a little over two decades.119-121 A comparison of SD and SFD techniques
would be highly useful in evaluating the design space of polymeric microparticles for inhalation.
SD involves solvent removal by evaporative cooling upon atomization. SFD involves freezing of
atomized droplets followed by solvent removal by sublimation and desorption through
lyophilization.42 Thermal sensitivity of materials such as small molecules, biopharmaceuticals, and
excipients is one of the major limiting factors to develop stable formulations. The risks associated
with the processing these materials are relatively high in SD when compared to SFD process.
Furthermore, the uniqueness of SFD to provide less density products compared to SD makes it
more sustainable method for the production of DPI’s. Few studies have directly compared these
two techniques for engineering inhalable particles.119, 122, 123 Maa et al.119 studied the influence of
SD and SFD processes, through same atomization, on physical properties and aerosolization of
protein powders. SD produced small and dense particles. However, SFD resulted in large porous
particles with better fine particle fraction (FPF) i.e. aerodynamic properties. Nguyen et al. 123
evaluated SD and SFD processes for engineering darbepoetin alfa microparticles with uniform size
distribution, to encapsulate into PLGA. This study used two different atomization processes.
Solutions for SD were atomized using 0.7 mm two-fluid nozzle. Whereas, solutions for SFD were
atomized using ultrasonic probe at 25 kHz and 120 kHz. SD was concluded to be a superior process
for engineering darbepoetin alfa particles for encapsulation. Brunaugh et al.122 studied the effect
of SD and SFD processes on aerosolization behavior of lysozyme particles. SD produced smaller
and denser particles. Whereas SFD produced large, low-density particles with large specific
surface area and rugosity. Furthermore, the study showed the implications of particle
characteristics on dispersion device selection and long-term stability.
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The current study focuses on the groundwork laid by these previous studies. We hypothesized
that the formulation composition as well as particle engineering technique would impact product
characteristics and result in differences in aerosolization behavior. Therefore, a controlled
experimental design to engineer SD and SFD microparticles was executed separately. SD
microparticles were engineered using sodium carboxymethyl cellulose (SCMC), sodium alginate
(SA), and sodium hyaluronate (HA) polymers in the formulation. SFD microparticles were
engineered using PLGA, polyethylene imine (PEI), and PVA. L-leucine and glucose were used to
enhance aerosolization properties and product stability upon SFD. Sildenafil citrate (SC) was used
as a model drug as it has been a drug of choice for pulmonary arterial hypertension (PAH).
Randomized clinical studies have demonstrated the safety and efficacy of sildenafil citrate in the
treatment of PAH in various populations including neonates.124-126 However, oral and IV
administration of sildenafil citrate products is associated with short biological half-life and
systemic side effects such as hypotension and headache. 127,
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Rashid et al.129

recently

demonstrated the effectiveness of inhalable over orally administered sildenafil citrate loaded
poly(lactic-co-glycolic acid) for PAH therapy. Therefore, SC was chosen as a promising drug for
the current study to examine the feasibility of formulating drug loaded-inhalable microparticles
with the controlled release and enhanced pulmonary delivery.
3.2.Materials
Sildenafil citrate (SC) [purity 98%] were gifted by Pfizer, Cairo, Egypt. Manucol® LD grade
of sodium alginate (SA) was received as a gift sample from FMC Corporation, Philadelphia, PA,
USA. Sodium carboxymethyl cellulose (SCMC), sodium hyaluronate (HA) [purity 95%, Catalog
no. AC251770050], L-leucine (Catalog no. BP385-100), PVA [Catalog no. AC396760250],
polyethyleneimine (PEI) branched (Catalog no. AA4502414), and Tween 80 were purchased from
Fisher Scientific, New Hampshire, USA. Poly(lactic-co-glycolic acid) [PLGA] 75:25, acid
terminated, inherent viscosity = 0.84 dL/g was purchased from Lactel Absorbable polymers, USA.
Dialysis tubing cellulose membrane (MWCO 14kD) anhydrous D (+) glucose were purchased
from Sigma Aldrich, St. Louis, USA.
3.3.Methods
3.3.1. Preparation of spray-dried microparticles
SC loaded spray-dried polymeric microparticles were prepared using a lab scale Buchi B-290
mini spray dryer (Buchi Labortechnik, Flawil, Switzerland) equipped with 0.7 mm two-fluid
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nozzle. The SA, SCMC, HA concentrations were varied according to three-factor, degree 3
extreme vertices mixture design with nine experimental runs, as described in Table 3-1 and Figure
3-1.
A total 1% w/v solid content was added to deionized water to prepare the feed solution. The
solid contents composed of sildenafil citrate, L-leucine, and Tween 80 that were maintained at 8
%w/w, 20 %w/w, and 0.01 %w/w, respectively, in all feed solutions. First, the SC and each of the
polymers/excipient (SA, SCMC, HA, and L-leucine) were separately dissolved in sufficient
volume of deionized water by stirring at 500 rpm for two hours to ensure complete swelling and
hydration of the polymers. Then, the SC and polymeric/excipient solutions were mixed by stirring,
followed by the addition of Tween 80 to prepare the feed solution. The final volume of the feed
solutions was adjusted to 120 mL with deionized water.
All feed solutions were spray dried at 150C inlet temperature, 50% ( 20 m3/h) aspiration,
2% ( 0.6 mL/min) solution feed rate, and 55 mm spray gas flow with external compressed gas
pressure maintained at 80 psi. The outlet temperature which depends on the feed rate, spray gas
flow and inlet temperature15 remained at 70C in all spray drying runs. The final product was
collected, weighed, and stored in 20 mL clear glass scintillation vial in a desiccator at room
temperature.

Figure 3-1. Schematic of the sildenafil citrate loaded polymeric microparticles formulation
development by spray-drying process.
3.3.2. Preparation of spray freeze-dried microparticles
Spray freeze-dried (SFD) polymeric microparticles were prepared by a three-step process that
involved double emulsion—solvent evaporation technique followed by spray freeze drying to
engineer inhalable SC loaded PLGA microparticles (Figure 3-2). Critical formulation components
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were mapped by applying experimental design concepts in two stages: (i) 2 1x21x31 factorial
screening design and, (ii) 21x21 factorial design.
Initially, SC-PLGA microparticles for SFD were prepared by double emulsion-solvent
evaporation technique. Briefly, 60 mg of SC was dissolved in 5 mL deionized water and the pH
was adjusted to 2.00 using 1 N hydrochloric acid. This SC solution serves as an internal aqueous
phase. Required amounts of PLGA and PEI (Table 3-2) were weighed in a glass breaker with 15
mL dichloromethane (DCM) and mixed to form an organic phase. The SC solution was added to
PLGA-PEI organic phase while homogenizing (D1000 Handheld Homogenizer, Benchmark
Scientific, USA) for 10 min at 5000 rpm to form a water-in-oil (W1/O) primary emulsion. PVA
dissolved at required amounts (Table 3-2) in 45 mL deionized water serves as an external aqueous
phase. The primary emulsion was added to PVA solution while homogenizing for 20 min at 5000
rpm to form a double emulsion (W1/O/W2). The DCM was evaporated by stirring the double
emulsion in a fume hood for 2 h. Particles were then collected after centrifugation for 10 min at
3000 rpm and double washing with 10 mL deionized water. These SC-PLGA microparticles were
suspended in feedstock solution of L-leucine and glucose for SFD.
Spray freezing drying process involved slight modification to Buchi B-290 mini spray dryer
(Buchi Labortechnik, Flawil, Switzerland) setup with 0.7 mm two-fluid nozzle. The drying
chamber was replaced with double-jacketed polypropylene vessel, carrying 500 mL liquid nitrogen
in a glass beaker under constant stirring at 500 rpm. The vessel was positioned such that the
distance between nozzle tip and liquid nitrogen surface was 10 cm. Microparticle feedstock
dispersion was atomized at 4 mL/min feed rate and 60 L/h atomizing air flow rate while
continuously mixing the dispersion at 250 rpm. The atomized droplets were immediately frozen
upon deposition in liquid nitrogen. The beaker with frozen droplets in liquid nitrogen were
transferred to VirTis Advantage v2.0 benchtop freeze dryer (SP Scientific, NY, USA), pre-chilled
to -50C shelf temperature. Droplets were maintained at -50C for 4 h to evaporate liquid nitrogen
residue. Later, the droplets were freeze-dried at -20C and 100 mTorr vacuum for 24 h followed
by secondary drying at 25C under same vacuum for 10 h. The freeze-dried product was finally
collected in a tightly closed 20 mL clear glass vial and stored in a desiccator at room temperature.
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Figure 3-2. Schematic of the sildenafil citrate (SC) loaded polymeric microparticles formulation
development by spray freeze- drying (SFD) process. A three-step process of double emulsion—
solvent evaporation technique followed by SFD to engineer inhalable SC loaded poly(lactic-coglycolic acid) [PLGA] microparticles. PEI- polyethylene imine; DCM- dichloromethane; DIdeionized; PVA- polyvinyl alcohol.
3.3.3. Lead product identification and characterization
Ideal formulations were characterized for morphology, entrapment efficiency (EE), and SC
release by our collaborator, Dr. Chablani’s group (Department of Pharmaceutical Sciences, St.
John Fisher College, Rochester, NY 14618, USA). In vitro aerosolization and tapped density
studies were investigated in our lab.
3.3.4. Optimized product characterization
3.3.4.1.

In vitro aerosolization studies

The aerosolization properties were studied using an eight-stage non-viable Andersen Cascade
Impactor (ACI) with preseparator (Westech Scientific Instruments, Bedfordshire, UK).
Hydroxypropyl methylcellulose hard capsules of size 3 (Vcaps ®, Capsugel®) were filled with
approximately 25 mg spray-dried (SD) microparticles, or 10 mg of spray freeze-dried (SFD)
microparticles. A low resistance mono-dose dry powder inhaler mouthpiece (Item code
239700001AB, Plastiape S.p.a. con socio unico, Lecco, Italy) was used to actuate microparticles
into the ACI. All ACI studies were performed for 30 s at 28.3 ± 1.4 L/min flow rate, under ambient
room conditions. Each stage was coated with polysorbate 20 (Alfa Aesar, Ward Hill, MA) to
ensure efficient particle capture and minimize particle bouncing. Formulations were tested in
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triplicate and their average values with corresponding standard deviations were reported. The mass
median aerodynamic diameter (MMAD), geometric standard deviation (GSD), percent emitted
dose recovery, and percent fine particle fraction (FPF) were calculated on formulation weight basis
by two-point interpolation method.
[3-1]

𝑑84.13
𝐺𝑆𝐷 = √
𝑑15.87

Where, d84.13 and d15.87 represent the diameters at which 84.13% and 1587% if the aerosolized
particles are contained.
3.3.4.2.

Modified tapped density

The United States Pharmacopoeia (USP) <616> tapped density method130 was slightly
modified to accommodate small volume samples.15 This was performed using a 250 µL glass
syringe (Part no. 81120, Hamilton®, Reno, NV) with a Leur lock (CTFE Hub needle, Part no.
16801, Hamilton®, Reno, NV). Briefly, an empty syringe weight with Leur lock was recorded and
a formulation was filled to 200 L with the aid of stainless-steel spatula. The mouth portion of
the glass syringe was closed with paraffin to avoid spillage. Above set-up was further fit into a 15mL centrifuge tube to simulate graduated measuring cylinder used in USP tapped density.
Complete assembly was then used for modified tapped density testing where the volume of sample
in the syringe was recorded after 10, 200, 500, 750, 1250 manual tappings. The volume occupied
after 1250 tappings was recorded and tapped density was calculated using equation 3-2.
Tapped density
=

[3-2]

[(Syringe weight with sample in mg) − (Empty syringe weight in mg)]
Sample volume after 1250 tappings in µL

3.3.5. Statistical analysis
All statistical analyses were performed using JMP ® v14.0.0 (SAS Institute, Cary, NC)
software. Sample means were compared by Student t-test, or analysis of variance (ANOVA)
followed by Tukey’s Honestly Significant Difference (HSD), whichever applicable. A p-value of
less than 0.05 was considered significant.
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3.4.Results and Discussion
3.4.1. Spray-dried formulations screening
A complex interplay of material attributes and process parameters on quality target product
profile demands for a scientifically integrated strategic approach to design a drug product. 15 An
extreme vertices type of mixture design was used to screen and identify lead SD formulations due
to its advantage to investigate small sub-portion of the composition within the overall formulation,
by a limited number of experiments, making the design construction as well as model fitting easier
over constrained region of interest.131
A total of nine formulations were prepared by applying constraints in the design to allow
variation of SCMC, SA, and HA over a predetermined range (Table 3-1). Selected response
variables – product yield %, particle size, span, EE%, and cumulative drug release – were
evaluated by a summary of fit and analysis of variance (ANOVA).
The product yield % of various mixture design formulations ranged between 30.3% and 65.6%
(Table 3-1). Statistically significant model was determined for yield % (p = 0.0222; R2 = 0.9925;
adjusted R2 = 0.9702). Only two individual components of the feed solution, SCMC (p = 0.0017)
and SA (p = 0.0010), showed a significant positive impact on the yield %; no interactions were
found significant. It is expected that the yield % will be directly proportional to the feed solution
concentration. Maltesen et al.132 reported that the efficiency of product yield is significantly
decreased at low feed solution concentration and target particle size. Counterintuitively, Vinjamuri
et al.15 reported that the individual feed solution concentration was insensitive to yield %. Instead,
the interdependence of feed solution concentration on process parameters was demonstrated. The
interaction of feed solution concentration with SGF and inlet temperature showed a positive and
negative impact, respectively, on product yield %. High variability in product yield is not
uncommon at a laboratory scale.15 We believe the investigated range of HA might not be diverse
enough for the design to model variability between the runs.
The particle size ranged from 2.05 µm to 10.13 µm, with relative standard deviations 20%.
ANOVA showed no significant impact of composition on particle size (p = 0.4091; R2 = 0.8392;
adjusted R2 = 0.3566). This could be due to low variability between the model and high error
associated within individual measurements, leading to a smaller difference between individual
sizes from the overall mean, and thereby poor predictability.
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1.88 ± 1.17
2.52 ± 1.39
2.11 ± 1.17
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7.17 ± 2.84
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4.43 ± 2.03
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(µm)*
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90.28 ± 0.02
92.20 ± 0.01

8.05 ± 0.00
6.60 ± 0.00
7.27 ± 0.00
6.58 ± 0.00
7.06 ± 0.01

100.60 ± 0.04
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82.20 ± 0.05
88.20 ± 0.10
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7.05 ± 0.00

88.07 ± 0.01
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Drug
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(%)*
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Efficiency
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*mean ± standard deviation
SCMC – sodium carboxymethyl cellulose; SA – sodium alginate; HA – sodium hyaluronate
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93.98 ± 5.50

106.63 ± 11.47

90.24 ± 2.58

97.00 ± 4.42

79.17 ± 18.32

82.89 ± 0.98

102.44 ± 15.2

111.51 ± 3.01

65.95 ± 7.42

Cumulative
Release after
24 h (%)*

Table 3-1. Extreme vertices mixture design for sildenafil citrate loaded spray-dried microparticles to evaluate formulation
parameter effects on the critical product properties

The particle size distribution, expressed as span, is one means of influencing inhalation
performance. Span values of <1.5 represent narrow particle size distribution. 133 The span of SD
formulations ranged between 0.63 and 2.52. Lowest values were observed for SDF2, SDF3, and
SDF6 formulations. Although the ANOVA was insignificant for span (p = 0.1771; R2 = 0.9371;
adjusted R2 = 0.7484), SCMC was found to show a significant positive influence on span (p =
0.0283) i.e. increasing the proportion of SCMC in the microparticles led to higher span values.
The span of SDF1 (containing 100% SCMC) was 2.18 while that of SDF6 (containing 50% SCMC
and 50% SA) was 0.65 (Table 3-1). Xu et al.134 reported that the spray-dried microparticles
composed of SCMC exhibited a broad particle size distribution with a mean diameter of 9.6 µm
and span of 3.7. The author suggested that this result was indicative of a degree of cohesion
between particles due to the presence of SCMC in the microparticles.
The EE% values of all mixture design formulation were >80%, and the mean value for most
of the formulations was 87%. Like particle size and span, the overall model turned out to be
insignificant (p = 0.5058; R2 = 0.7906; adjusted R2 = 0.1626). However, the presence of SCMC (p
= 0.0033) and SA (p = 0.0029) in the microparticles were found to show a significant positive
influence on EE% values
The cumulative SC release from SD formulation at 24 h ranged between ~66% and ~112%.
ANOVA showed no significant (p = 0.8035; R2 = 0.5814; adjusted R2= -0.6745) impact of SD
microparticles composition on SC release profile.
3.4.2. Spray freeze-dried formulation screening
SFD has emerged as a promising technique for the production of inhalable powders. Based on
preliminary studies, SC solution pH, PLGA to SC ratio, PEI addition to hydrophobic PLGA phase
in the primary emulsion and use of PVA as emulsifier in the secondary emulsion were found
influence SC partitioning to the aqueous phase. Furthermore, L-leucine and glucose concentration
in feedstock solution was found to influence percent yield and moisture content. It was
hypothesized that the microparticles and feedstock compositions show significant influence on
yield %, particle size, span and EE%. Accordingly, PLGA, PEI, and PVA concentrations, at
selected levels from preliminary studies, were investigated by initial 2 1x21x31 factorial screening
design. The impact of L-leucine and glucose concentration in feedstock solution were studied
during optimization. Process parameters in both the stages were held constant based on prior
knowledge.
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0.5 [-1]

1.0 [+1]

300 [+1]

SFDF5

180 [-1]

0.5 [-1]

300 [+1]

SFDF4

SFDF7

0.5 [-1]

180 [-1]

SFDF3

0.5 [-1]

0.5 [-1]

300 [+1]

SFDF2

300 [+1]

1.0 [+1]

300 [+1]

SFDF1

SFDF6

PEI (% w/v)

Composition

PLGA (mg)

Formul
ation

87.33 ± 0.03

83.98 ± 0.39

90.90 ± 0.06

94.48 ± 1.93

12.75 ± 2.63

9.97 ± 0.14

3.02 ± 0.02

92.99 ± 0.28

10.67 ± 3.92

4.89 ± 1.23

4.02 ± 0.16

81.65 ± 0.08

Entrapment
Efficiency
(%)

Table 3-2. A 21x21X31 factorial design to the effect of formulation composition on spray freeze-dried sildenafil
citrate loaded poly(lactide-co-glycolide) microparticle properties

A total of twelve formulations were prepared at various PLGA, PEI, and PVA concentrations

over a predetermined range (Table 3-2). Designated response variables—yield%, size, span, and

EE%—were evaluated by summary of fit and ANOVA.

The SFD product yield% obtained from the factorial screening design experimental trails
ranged between 20.38% and 48.70% (Table 3-2). A statistically significant model was determined
for percent yield (p = 0.0003; R2 = 0.9938; adjusted R2 = 0.9830). Percent yield was significantly
affected by individual PEI (p<0.0001) and PLGA (p=0.0007) concentrations along with their two
factor interactions (p=0.0493). PLGA showed a negative effect on percent yield. This could be
due to enhanced viscosity of the feed stock dispersion used for SFD. An increase in PEI from 0.5
%w/v to 1.0 %w/v increased the yield %. PEI increased the entrapment of SC within the
microparticles by creating a hydrophilic region that reduced SC escape into the external aqueous
phase and led to an increase in the percent yield. The two-factor interactions are seen in the event
of interdependent impact of the two variables on the corresponding outcomes. In this case, a
positive interaction between the PEI and PLGA represents synergistic effect. This implies that
larger PEI concentration has more positive effect on yield with an increase in PLGA. Additionally,
PVA showed a significant (p=0.0009) curvilinear relationship with yield %, which suggests a
negative quadratic correlation between the variables.
The size of SFD polymeric microparticles obtained from the factorial design formulations
ranged between ~8 µm and ~30 µm, respectively (Table 3-2). ANOVA showed no significant
(p=0.0514; R2 = 0.9130; adjusted R2 = 0.7608) influence of formulation variables on particle size.
Likewise, the formulation variables showed no significant (p = 0.7192; R2 = 0.5261; adjusted R2
= -0.3031) influence on span of the SFD microparticles. The negative adjusted R2 is an indication
that the selected range of formulation variables provided negligible explanation towards span,
likely due to narrow design space.
The EE% of SC in SFD formulations obtained within the design space of predetermined
formulation variables ranged between ~3% and ~95%. ANOVA showed significant (p<0.0001; R2
= 0.9997; adjusted R2 = 0.9990) influence of formulation variables on EE %. The PLGA showed
a significantly (p=0.0193) negative correlation with EE%. High proportion of PLGA increased the
hydrophobicity of the organic phase and subsequently reduced the entrapment of hydrophilic SC
in the polymeric matrix. Nevertheless, correlation plot with EE displayed relatively smaller slope
for PLGA when compared to PEI, suggesting the minimum influence of PLGA on EE when
compared to PEI. The PEI showed a significant (p<0.0001) positive influence on EE%. However,
its squared term showed a significant (p=0.001) negative correlation with EE%. The two-factor
interaction between PEI and PVA indicated a significant (p=0.0074) negative effect on EE%.
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3.4.3. Lead SD and SFD formulations
Lead SD formulation were screened by mapping desired response variables in the mixture
profilers. Upon computing the mixture design and adding contour plots based on the five
predefined responses—yield % (>45%), particle size (1 to 5 µm), span (<1.5), EE% (>80%) and
cumulative drug release (>85%) at 24 h—three SD polymeric microparticle formulations SDF2,
SDF3, and SDF6 were screened within the target space. These formulations were further
characterized for in vitro aerosolization and tapped density.
Lead SFD formulation were screened by mapping desired response variables in the 21x21x31
factorial design contour profilers. Upon computing the design and adding contour plots based on
four predefined responses—yield% (>40%), size (6 to 20 m), span (<1.5), and EE% (>80%)—
two SFD formulations namely, SFDF5 and SFDF9, were screened within the target space.
Ultimately, F9 was considered ideal due to relatively superior desired properties
Table 3-3. Cryoprotectant optimization studies of spray freeze-dried sildenafil citrate loaded
poly(lactide-co-glycolide) microparticle
LEntrapment
Glucose
Yield
Formulation Leucine
Size (µm)*
Span*
Efficiency
(%w/v)
(%)
(%w/v)
(%)*
11.45 ±
SFDF9A
10
15
25.00 11.86 ± 2.89
94.60 ± 0.15
2.41
SFDF9B

10

25

27.69

9.83 ± 2.40

1.30 ± 0.04

94.70 ± 0.20

SFDF9C

30

15

49.30

8.27 ± 1.70

1.01 ± 0.15

94.20 ± 0.06

SFDF9D

30

25

52.30

8.59 ± 1.47

1.00 ± 0.27

94.30 ± 0.35

*mean ± standard deviation, n=3
The cryoprotectant used in the SFD process usually influences the physicochemical properties
and stability of a finished product. 135 Cryoprotectant is usually added to protect the microparticles
from the mechanical stress due to ice crystal formation and prevent aggregation. This underlines
the need to evaluate the effect of cryoprotectant on yield%, size, span, and EE%. Glucose was
selected as a cryoprotectant based on preliminary studies (data not shown). It was investigated
between 15%w/v and 25%w/v in the feedstock solution. Additionally, L-leucine was added to the
feedstock dispersion to prevent agglomeration and enhance aerosolization behavior of the SFD
microparticles.15, 136 L-leucine was investigated between 10%w/v and 30%w/v (Table 3-3). The
yield of these formulations ranged between 25% and 52%. The size ranged from 7 m to 14 m
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and the span ranged from 1 to 14. High span in SFDF9A (11.45) was likely due to particle
agglomeration during the SFD process. All four SFD formulations showed high EE (94%). The
results (Table 3-3) indicate negligible effect of glucose on SFD microparticles. Therefore,
SFDF9C and SFDF9D were considered for further characterization due to high yield %.
3.4.4. Aerosolization of optimized SD and SFD formulations
Aerodynamic particle size distribution (APSD) of an orally inhaled product is understood to
be a critical quality attribute by the regulatory agencies 137-139 because these properties are
correlated to predict the fate/deposition of microparticles in the lungs after pulmonary
administration. MMAD is one of the fundamental factors that control particles deposition in the
lungs. The particle size of inhalable formulations must be in size range of 1 µm to 5 µm for efficient
deep lung delivery. Particles less than 1 µm could be exhaled shortly after inhalation while
particles more than 5 µm would deposit in the large conducting airways and oropharyngeal
region.140 Therefore, controlling particle size is essential for the development of effective
pulmonary drug delivery system.
The ACI deposition profiles and aerosolization parameters of the SD and SFD polymeric
microparticles is illustrated in Figure 3-3. Reported MMAD and GSD values were calculated from
the two-point interpolation method141, also known as a cumulative percent mass method.
The MMAD’s of lead SD microparticles SDF2, SDF3, and SDF6 were 4.63 ± 0.28 μm, 4.79 ±
0.19 μm, and 4.67 ± 0.25 μm, respectively. The MMAD’s of lead SFD formulations SFDF9C and
SFDF9D were 4.52 ± 0.37 μm and 4.19 ± 0.16 μm, respectively. All formulations showed MMAD
values less than 5 μm within the inhalable size range.142 No significant difference was observed
between the MMAD’s of SD and SFD polymeric microparticles.
GSD represents the distribution of polymeric microparticles within the eight stages of the ACI.
The GSD’s of lead SD polymeric microparticles SDF2, SDF3, and SDF6 were 1.79 ± 0.38, 1.59
± 0.13, and 1.69 ± 0.11, respectively. The GSD’s of SFD microparticles SFDF9C and SFDF9D
were 2.05 ± 0.27 and 2.59 ± 0.10, respectively. SFD polymeric microparticles showed relatively
higher GSD’s than SD microparticles. The SFDF9D polymeric microparticles displayed
significantly (p<0.05) broader GSDs than all SD polymeric microparticles. Among lead SFD
formulations, SFDF9D were significantly (p=0.0332) polydisperse with broad particle size
distribution than SFDF9C microparticles. This was reflected in product deposition profiles (Figure
3-3). Noticeably high microparticle depositions were observed in the induction port and the
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preseparator than the eight ACI stages. No significant (p>0.05) difference was noticed within the
GSD’s of lead SD formulations.
Emitted dose recovery % is the total amount formulation deposited in induction port,
preseparator, stages 0 through 7, and filter to the theoretical amount of the loaded formulation
times 100 (Figure 3-3). It is an indicator of an effective emptying of a dose from the inhaler device.
The percent emitted dose recovery of lead SD microparticles SDF2, SDF3, and SDF6 from the
cascade impaction studies were 85.31 ± 5.49 %, 67.97 ± 1.54 %, and 79.68 ± 9.20 %, respectively.
Likewise, the percent emitted dose recovery of lead SFD polymeric microparticles SFDF9C and
SFDF9D from the cascade impaction studies were 90.12 ± 6.65 % and 97.68 ± 1.07%, respectively.
Such high percent emitted dose recovery indicates the effective emptying of all the lead SD and
SFD microparticles from the inhaler device. This complies with the United States Pharmacopeia
(USP) monograph <601>143 which requires the mass of drug substance deposition in all the ACI
components to be between 85% and 115% to ensure the validity of test results. However, SFD
microparticles displayed relatively better mass recoveries than SD microparticles. The emitted
dose recovery % of SFDF9D is significantly (p<0.05) higher than all SD formulations. Among SD

Deposited Formulation (%)

formulations, SDF2 and SDF6 showed high mass recoveries compared to SDF3 microparticles.
50
45
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35
30
25
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15
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5
0

ACI Stages

SDF2

SDF3

SDF6

SFDF9C

SFDF9D

Figure 3-3. Percent depositions of spray-dried (SDF2, SDF3, SDF6) and spray freeze-dried
(SFDF9C and SFDF9D) formulations in various parts of the Andersen Cascade Impactor (ACI)
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Figure 3-4. Cumulative mass deposition of spray-dried (SDF2, SDF3, SDF6) and spray freezedried (SFDF9C and SFDF9D) formulations as a function of effective cut-off diameters
FPF is the fraction of API/formulation deposited under the effective cut-off diameter (ECD),
calculated within the recovered formulation percent. In this study, 4.7 μm was considered as the
ECD. Therefore, the FPF would be the total amount deposited in stage ‘3’ through the filter to the
total formulation recovered. The FPF% of SD polymeric microparticles SDF2, SDF3, and SDF6
were 24.29 ± 6.89 %, 27.52 ± 5.35 %, and 30.04 ± 5.53 %, respectively. The FPF% of SFD
polymeric microparticles SFDF9C and SFDF9D were 25.33 ± 3.32 % and 18.03 ± 1.06 %,
respectively. SD formulations showed relatively better FPF% than SFD formulations. Similar
results have been commonly reported for spray-dried formulations.118, 122, 123, 144 Generally, higher
FPF% would be more favorable to ensure the delivery of sufficient dose to the lungs. This could
be achieved by the further optimization, perhaps by the addition of standard excipient carriers such
as lactose or mannitol that are widely used in conventional DPI formulations.145, 146 Among, lead
SD formulations, SDF6 exhibited higher percent FPF% compared to SDF2 and SDF3
formulations. However, no statistical difference was observed between the FPF % of these
formulations (p>0.05). Among lead SFD formulations, SFDF9C exhibited significantly
(p=0.0222) higher FPF% than SFDF9D. Relatively low FPF values, in this case, were observed
due to high depositions in the induction port, pre-separator, and stage 0 of the ACI (Figure 3-3).
Similar FPF% was reported with the PLGA based nanoaggregates SFD microparticles prepared
with PVA and leucine.121

56

3.4.5. Tapped density of lead SD and SFD formulations
Figure 3-5 shows tapped density values of SC-loaded SD and SFD polymeric microparticles.
The tapped density of microparticles produced from spray drying process were about seven-fold
higher than the spray freeze-drying process.
The tapped densities of SDF2, SDF3, and SDF6 polymeric microparticles were 0.713 ± 0.011
g/mL, 0.746 ± 0.049 g/mL, and 0.776 ± 0.067 g/mL, respectively. To determine the effect of SC
loading on the tapped density, the SD SC-loaded active formulations along with corresponding
placebos were tested. The tapped density values of the placebo SD placebo formulations ranged
between 0.45 g/mL and 0.62 g/mL. No statistical difference was observed between the tapped
densities of the three SD formulations—SDF2, SDF3, and SDF6 (p>0.05). The SD placebo
polymeric microparticles of all three formulations showed lower tapped density than the
corresponding active microparticles (data not shown). This may be due to the lack of drug load in
the placebo microparticles.
The tapped density of SFDF9C and SFDF9D formulations were found to be 0.072 ± 0.007
g/mL and 0.112 ± 0.024 g/mL, respectively. SFDF9C formulations showed a significantly
(p=0.0493) lower density than SFDF9D formulations (Figure 3-5). Low SFDF9C tapped density
is likely due to high L-leucine and low glucose proportions in comparison to SFDF9D (Table 3-

Tapped Density (g/mL)

3).
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Figure 3-5. Tapped density of spray dried (SD) and spray freeze-dried (SFD) sildenafil citrate
loaded polymeric microparticles
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3.5.Conclusion
Mixture design was successfully implemented to engineer inhalable SD SC-loaded polymeric
microparticles. Likewise, factorial designs were successfully implemented to engineer inhalable
SFD SC-loaded polymeric microparticles. From the profilers and statistical evaluation, it was
concluded that polymers could be used at different concentration and combinations to produce
microparticles with high yield%, EE%, suitable particle size. We found that the formulation
composition as well as particle engineering technique would impact tapped density and result in
differences in aerosolization behavior. SFD resulted in large light particles. SD product small
dense particles. The results of the MMAD, GSD, and emitted dose recovery % of the developed
formulations were promising and indicated that both the SD and SFD polymeric microparticles
possess good aerosolization properties. However, particles engineered by SD demonstrated
relatively superior aerodynamic characteristics than SFD.
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Chapter 4 : GELATIN SOLUTION pH AND INCUBATION TIME INFLUENCES THE
SIZE OF THE NANOPARTICLES ENGINEERED BY DESOLVATION
Abstract
Gelatin nanoparticles (GNPs) have been extensively engineered by desolvation processes.
However, engineering monodisperse GNPs of reproducible size remains a challenge. Therefore,
the starting material processing steps such as gelatin solution pH adjustment and incubation time
prior to desolvation were investigated to understand their implications on GNPs size and size
distribution. The GNPs were engineered by one-step and two-step desolvation processes using
ethanol as a desolvating agent. Irrespective of the desolvation steps, gelatin solution pH incubation
times between 0 h and 24 h showed significant (p<0.05) increase in GNPs size. This phenomenon
was distinctly observed in GNPs engineered by one-step desolvation process. Additionally, twostep desolvation process resulted in relatively smaller monodisperse GNPs compared to one-step
desolvation. Statistical rationales from traditional One-Factor-at-a-Time analysis corroborated the
multivariate correlations derived from principal component analysis and standard partial least
square-1 (PLS-1) regression. Significant predictive model equations to compute GNPs size and
size distribution were modeled by PLS-1 regression and verified with experimental values. Our
findings demonstrated the statistically significant (p<0.05) decisive roles of gelatin solution pH
and incubation time on size and size distribution of GNPs engineered by desolvation process.
Furthermore, irrespective of incubation times, GNPs from two-step desolvation maintained
relatively better physical stability for 238 days in terms of size and size distribution than one-step
desolvation.
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4.1.Introduction
Protein-based nanopharmaceuticals have witnessed tremendous progress over the last few
decades. This is attributed to their unique physicochemical properties at cellular and molecular
levels, which are not usually seen with conventional drug products. Yet, limited number of proteinbased nanoparticle products have been translated to clinical trials and received regulatory
approvals. This is evident from <14% of nanopharmaceutical drug product applications received
by the FDA between 1970 and 2015 pertinent to protein complexes as well as protein based
polymeric nanoparticles.25
Gelatin has been an extensively investigated biodegradable natural protein among the proteinbased nanopharmaceuticals to deliver small- and macro-molecules.4 Despite the mounting research
and technical advancements triggered by the promising prospects, no gelatin nanoparticles (GNPs)
product has reached the clinic. This might be due to the numerous challenges associated with
protein-based formulation components and manufacturing procedures during the early
development. Any pharmaceutical product development is a complex interplay of the raw material
physicochemical properties and the manufacturing procedures. Moreover, it is critical to delineate
a robust manufacturing process to engineer a product without batch-to-batch variability.
Proteins like gelatin are susceptible to diminutive environmental changes like temperature, pH,
ionic strength etc., This poses stability concerns while handling during the manufacturing process.
Additionally, the down-stream manufacturing process involves numerous steps such as the use of
organic solvents, mixing, evaporation, crosslinking, centrifugation, filtration, lyophilization and
occasional sterilization. We believe, an in-depth understanding of the interplay between the
materials physicochemical attributes and processing conditions might be fundamental to establish
highly reproducible manufacturing procedures for GNPs production. Therefore, we identified the
need to investigate the interplay of key under-studied formulation as well as process parameters in
GNPs product development by the conventional bivariate One-Factor-at-a-Time (OFAT) analysis.
We further recognized the need to integrate multivariate statistical tools to derive pragmatic
predictive models and scientific rationales within the experimented design space.
Desolvation methods are widely used to engineer therapeutic agent loaded GNPs.37, 53, 54 The
process involves the dissolution of gelatin and therapeutic agent in an aqueous solvent, followed
by the controlled addition of an organic solvent to obtain nanoparticles. Aqueous gelatin solution
comprises of gelatin and an aqueous solvent that are bound predominantly by hydrogen bonding

60

in a single phase. Addition of a desolvating agent, such as ethanol or acetone, initiates the
breakdown of these hydrogen bonds and replacement of water molecules surrounding the gelatin
with a desolvating agent. This eventually leads to folding or restructuring of gelatin fragments into
aggregate structures. The gelatin aggregates, thus formed, are ultimately crosslinked with a
suitable chemical crosslinker to ingrain physical stability.
One-step desolvation was the first reported process to engineer GNPs of larger size and broad
size distribution.37 However, the process is plagued by non-uniform aggregate formation before
and after crosslinking due to heterogeneity in the gelatin molecular weight. Coester et al. 53
introduced a second desolvation step before crosslinking to generate relatively uniform sized
particles with narrow size distribution. Two-step desolvation involves the removal of low
molecular weight (LMW) gelatin fraction dissolved or dispersed in the solvent phase, while
precipitating the high molecular weight (HMW) fraction, during the first desolvation step. The
precipitated HMW fraction would be re-dissolved in an aqueous solvent and desolvated again to
form small uniform sized particulates. Ofokansi et al.54 developed a simplified one-step
desolvation process owing to the tediousness associated with the above two processes. It involves
pH adjustment of gelatin aqueous solution to neutral values before desolvation to impart a net
negative or positive charge on gelatin. The process does not include the removal of LMW gelatin
fraction after desolvation step. The charge would induce intra- and inter-molecular attractions or
repulsions in gelatin chain, thereby leading to controlled entanglement of the protein fragments to
form uniform sized nanoparticles.
Particle size is one of the critical factors governing the nanoparticle degradation and in vivo
kinetics.61 The cellular uptake of nanoparticles by endocytosis are influenced by size and size
distribution. Previous studies have shown size modulations in the desolvation procedure due to
various reaction parameters such as desolvation steps53, gelatin type55-59, gelatin concentration60,
gelatin solution pH54,
temperature55,

57,

55, 57-59, 61,

desolvating agent type55,

crosslinker concentration54,

55, 62,

56,

amount of desolvating agent61,

and crosslinking time54. However, to our

knowledge, studies elucidating the impact of gelatin solution processing times, desolvation rate,
and crosslinker addition rate on size and size distribution have not been reported. We
hypothesized that gelatin solution pH and incubation time before desolvation plays a crucial role
to engineer GNPs of reproducible size and size distribution.
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Gelatin as a starting material, when dissolved in aqueous solvent, is extremely sensitive to
environmental conditions such as pH and temperature. The solution viscosity above gelation
temperatures changes slowly at pH values other than the isoelectric point. Additionally, the gelatin
solution viscosity at a given pH, other than the isoelectric point, either increases or decreases with
incubation time.147 Therefore, we slightly modified the reported processes with an objective to
understand the implications of the starting material attributes, namely pH and incubation time on
gelatin solution viscosity, and eventually on the size and size distribution of GNPs engineered with
different desolvation steps. Ethanol was used as a desolvating agent as it is clinically approved in
the pharmaceutical products by the FDA for parenteral administration. Genipin was used as a
crosslinker as it is a natural compound with relatively less cytotoxicity compared to widely utilized
glutaraldehyde.148 Initial experiments were conducted by traditional OFAT approach. Later, the
impact of main effects, interactions, and squared terms were modeled using multivariate statistical
tools. Furthermore, the impact of freeze-thaw cycle and ambient conditions on GNPs physical
stability up to 265 days were investigated.
4.2.Materials
MedellaPro® gelatin (191 g Bloom; Lot no. 7323-2C) was obtained as a gift sample from Gelita
USA Inc. (Sergeant Bluff, IA, USA). Gemcitabine hydrochloride (>98%; Lot no. P4UDM) and
genipin (Catalog no. 078-03021; Lot no. WEE4931) were purchased from Tokyo Chemical
Industries America (Portland, OR, USA) and Wako Pure Chemical Industries Ltd (Osaka, Japan),
respectively. Ethanol (200 proof; Catalog no. 2701; Lot no. 151812) was purchased from Decon
Laboratories Inc (King of Prussia, PA, USA). Hydrochloric acid [HCl] (12.1N; Catalog no. A144;
Lot no. 171938) and sodium hydroxide [NaOH] beads (ACS grade; Catalog no. BHD0292; Lot
no. 97821) were procured from Fisher Chemicals (Hampton, NH, USA) and VWR International
LLC (West Chester, PA, USA), respectively.
4.3.Methods
4.3.1. OFAT analysis design and response variables
Key under-studied formulation and process parameters among the reported GNPs were
selected as the study variables. The design (X) variables include desolvation steps, gelatin solution
pH, and incubation time of pH adjusted gelatin solution. The response (Y) variables include size
and polydispersity index (PDI). For readability, the “gelatin solution pH” will be referred as ‘pH’

62

and the “incubation time of pH adjusted gelatin solution” will be referred as ‘incubation time’
throughout the manuscript.
4.3.2. Gelatin solution pH and zeta potential
MedellaPro® gelatin (1.00 g) was dissolved in 100.0 mL MilliQ ® water at 40 ± 2 °C and 300
rpm mix speed for 30 min. Solution was adjusted to desired pH with 1.0 N HCl or 1.0 N NaOH
solutions under constant mixing. The pH was measured using a Seven Compat pH meter (Mettler
Toledo LLC, Columbus, OH) equipped with InLab® Expert Pro-ISM (Order no. 30014096),
calibrated and verified as per the United States Pharmacopoeia <791>149.
Zeta potential was measured using a Zetasizer Nano-ZS (Malvern Instruments Ltd.,
Worcestershire, UK). Exactly 5 min after pH adjustment, solution was loaded into a disposable
folded capillary cell (Catalog no. DTS1070) and equilibrated at 37.0 ± 0.2 °C for 60 s. Each
solution was then measured in triplicate in which a measurement was an average of 50 scans. Raw
data was processed using Malvern Zetasizer v7.12 software (Malvern Instruments Ltd.,
Worcestershire, UK).
4.3.3. Gelatin solution viscosity
MedellaPro® gelatin (2.50 g) was dissolved in 50.0 mL MilliQ® water at 40 ± 2 °C and 300
rpm mix speed for 30 min.
Kinematic viscosity () of gelatin solution at varied incubation times was estimated using
Ostwald viscometer (Size 50; Catalog no. 9721-Y53; Cannon Instrument Company, PA, USA)
under the assumption that the gelatin solutions are Newtonian fluids at 40 ± 2°C. This temperature
is above the gelation point where the gelatin chains structural rigidity are reported to be absent 147.
Calculations were performed using Equation 4-1, assuming that the kinematic viscosity and
density () of water at 40°C are 0.6579 cSt and 0.9922 g/mL, respectively. All measurements were
conducted in triplicate.
ν1 ρ1 ν2 ρ2
=
t1
t2

[4-1]

Where ‘t’ represent time in seconds
4.3.4. GNPs preparation
Gemcitabine-loaded active and placebo GNPs were prepared by slight modification of the
reported one-step and two-step desolvation processes.53,
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Figure 4-1 provides a schematic

illustration of the unit operation used to engineer GNPs. MedellaPro ® gelatin (2.50 g) was
dissolved in 50.0 mL MilliQ® water at 45 ± 2 °C and 300 rpm mix speed for 30 min.

Figure 4-1. Unit operations setup adopted to engineer gelatin nanoparticles by desolvation
One-step desolvation process was initiated by pH adjustment. Gelatin solution pH was adjusted
to 2.50 ± 0.05 with 1.0 N HCl. Under constant mixing at 500 rpm and 45 ± 2 °C, 1000 µL
gemcitabine aqueous solution (2.03 mg/mL) was added to 7.00 ± 0.03 mL of pH 2.5 gelatin
solution in a mobile phase glass bottle (100 mL capacity) to engineer gemcitabine-loaded active
GNPs. This gemcitabine solution was substituted with MilliQ ® water to engineer placebo GNPs.
Exactly 5 min after the equilibration at 45 ± 2 °C, ethanol (60 mL) was added to the solution at
1.00 mL/min using a syringe pump (Model no. 300; New Era Pump Systems Inc.) equipped with
60 mL plastic syringe (Reference no. 309654; Becton Dickinson syringes). After ethanol addition
was completed, 500 µL of genipin ethanolic solution (1.26 mg/mL) was added to the dispersion at
0.10 mL/min and mixed for 5 h to crosslink the GNPs. Subsequently, the engineered GNPs were
stored at ambient conditions for further studies.
Two-step desolvation was initiated by desolvation. Under constant mixing at 300 rpm and 45
± 2 °C, 100 mL ethanol was added to 50 mL gelatin solution (5 %w/v). After 2 min mixing
followed by 1 min resting at ambient temperature, the supernatant was discarded. Collected
gelatin precipitate was redissolved in 50.0 mL MilliQ® water at 45 ± 2 °C and 300 rpm mix speed
for 30 min. The pH was then adjusted to 2.50 ± 0.05. The remaining steps to engineer GNPs were
analogous to the one step desolvation process.
Incubation times in both one-step and two-step desolvation processes were varied between 0 h
and 24 h after adjusting the gelatin solution pH. The remaining formulation components and
process parameters were determined based on preliminary screening and held constant throughout
the study.
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4.3.5. Size and PDI
GNPs size and PDI were measured using a Zetasizer Nano-ZS (Malvern Instruments Ltd.,
Worcestershire, UK). Sample (50 µL) in disposable cuvette (Catalog no. ZEN0040) was
equilibrated at 25.0 ± 0.2 °C and measured at 173° backscattering, 0.001 absorption, and 0.8872
cP viscosity. Protein and water were chosen as material and dispersant, respectively. Each
measurement was an average of 30 scans with 5 s scan time and automatic attenuation. Raw data
was processed using Malvern Zetasizer v7.12 software (Malvern Instruments Ltd., Worcestershire,
UK).
4.3.6. Specific gravity of GNPs
Specific gravity was determined gravimetrically with 2 mL pycnometer (Corning®). The initial
weight of an empty pycnometer was recorded (W1). The gross weight (W2) of a pycnometer was
recorded after loading samples stored at desired temperatures. Each sample was tested in triplicate
and the specific gravity was calculated using Equation 4-2.
Specific gravity =

(w2 − w1 )sample
(w2 − w1 )control

[4-2]

4.3.7. Preliminary stability studies
Preliminary stability assessment was conducted on placebo GNPs engineered by a two-step
desolvation of pH adjusted gelatin solution incubated for 0 h. An aliquot of placebo GNPs batch
was subjected to freezing in an isopropanol-dry ice bath for 5 h followed by thawing at ambient
temperature for 1 h. Size and PDI of freeze-thaw treated GNPs were monitored for 30 days,
whereas the untreated GNPs were monitored for 265 days. Additionally, size and PDI of the GNPs
engineered by one-step and two-step desolvation of gelatin solutions at different incubation times
was monitored for 238 days.
4.3.8. Statistical analysis
A two-phase strategy was applied to evaluate multidimensional dataset generated from specific
questions discussed in the introduction.
The first phase involves conventional OFAT bivariate data analyses using JMP ® v14.0.0
software (SAS Institute, Cary, NC). Sample means were compared by Student t-test, or one-way
analysis of variance followed by post-hoc test, wherever were applicable. Welch’s test was used
when the variance between two samples was unequal during Student t-test. A p-value of <0.05
was considered statistically significant.
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In the second phase, a generated dataset composed of various design variables like desolvation
steps, pH, and incubation time with responses such as GNPs size and PDI were evaluated by
multivariate analyses using Unscrambler® v10.3 software (CAMO AS, Trondheim, Norway). A
qualitative principal component analysis (PCA) was performed to decode the hidden data patterns
of multidimensional dataset. Qualitative PCA relationships were quantified with a standard partial
least square-1 (PLS-1) regression. Both PCA and PLS-1 regression were performed on weighted
and scaled values of factors as well as response variables with their standard deviations. Full crossvalidation and Jack-Knifing methods were deployed to predict the uncertainty of the PLS-1
regression coefficients.150 The statistical significance of the regression coefficients was determined
at p<0.05. More details about the PCA and PLS-1 can be found elsewhere.151, 152
4.4.Results and Discussion
4.4.1

Effect of pH on gelatin solution zeta-potential

Zeta potential is an indicator for the net surface charge of a molecule or a particle in dispersion.
Uniform distribution of charges on gelatin chains are important for steric hindrance, to achieve
maximum stretching of the gelatin chains during the transformation from helix to coil
conformation. The extent of ionization of polar functional groups and subsequent charge
distribution in gelatin depends on the solution pH. Furthermore, gelatin assumes coil confirmation
in aqueous solutions. This coil confirmation at a given pH provides flexibility to gelatin chains to
reorient and collapse upon desolvation to form GNPs. We therefore identified the need to
understand the correlation between gelatin solution pH and zeta potential to engineer GNPs of
desired size and size distribution.
The pH and zeta potential of freshly prepared 1% w/v MedellaPro ® gelatin solution was 5.40
 0.05 and 5.56  0.10 mV, respectively. Its surface charge being close to zero (0.16  0.08 mV)
at pH 7.8 confirms MedellaPro® as a type-A gelatin. The isoelectric point of type-A gelatin is
usually between 7.0 and 9.0.4, 46
pH changes over the range from 1.5 to 7.8 led to 115-fold reduction in the surface charge,
suggesting gelatin deprotonation with an increase in pH (Figure 4-2). This is due to the ionization
of carboxylic acid (-COOH) and amine (-NH2) functional groups of acidic and basic amino acids,
respectively. About 13% of gelatin is composed of acidic amino acids and 8% is composed of
basic amino acids.153 Acidic amino acids like glutamic and aspartic acids are ionized to
carboxylates (-COO–) in the pH range of 2.0 to 6.5 and acquire a negative charge. Correspondingly,
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basic amino acids like lysine, histidine, and arginine are ionized to ammoniumyl (-NH3+) and
assumes positive charge. Lysine and histidine are ionized between pH 6.5 and 11.5, while arginine
is ionized at pH >1.15.153 We believe this net charge is responsible for inter- and intra-molecular
attractive or repulsive forces in gelatin chains.
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Figure 4-2. Influence pH on surface charge of the 1 %w/v MedellaPro® gelatin aqueous solution
The pH adjustment to acidic conditions, 2.5, significantly (p=0.0007) increased the zeta
potential from 5.56  0.10 mV to 18.33  2.35 mV. As mentioned earlier, this is due to protonation
of -COO– and -NH2 in gelatin chains to -COOH and -NH3+, respectively. A decrease in the zeta
potential below pH 2.5 might be attributed to counter chloride ions from the HCl solution added
for pH adjustment. Coester et. al.53 reported that gelatin peptide chains are electrostatically
stabilized at high surface charge due to greater repulsive forces.
The pH adjustment to slightly basic conditions, 7.8, significantly (p<0.0001) decreased the
zeta potential of gelatin solution from 5.56  0.10 mV to 0.16  0.08 mV. This is due to the
deprotonation of -COOH and -NH3+ to -COO– and -NH2, respectively. At surface charge close to
zero, the attractive forces exceed repulsive forces and lead to aggregation of gelatin molecules
4.4.2

Effect of pH incubation time on gelatin solution zeta potential and viscosity

Resistance to the flow of gelatin solution will arise largely due to inter- and intra-molecular
forces in gelatin chains. However, the type and magnitude of these forces are primarily dependent
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on solution pH, which regulates the net surface charge on gelatin chains. A list of possible
interactions in gelatin chains in decreasing order of the magnitude include: (i) Coulombic or ionion forces between oppositely charged ions (-COO– and -NH3+); (ii) ion-dipole forces between COO– on one chain and -NH2 on the other and vice versa; (iii) hydrogen bonding between >C=O
and H–N<; (iv) London dispersion forces between non-polar groups on gelatin chains; and (v)
mechanical entanglements between the long chains as observed with non-polar polymers in ideal
solvents.147
The pH of unadjusted gelatin solution remained stable at 5.4 during the 24 h incubation
(Figure 4-3A). The term ‘unadjusted’ throughout the manuscript refers to freshly prepared gelatin
solution without pH adjustment. Whereas the term ‘adjusted’ refers to gelatin solution with pH
adjusted to 2.50  0.05 using 1.0 N HCl solution to achieve maximum protonation. The pH and
zeta potential of ‘as is’ and desolvated adjusted gelatin solutions were same and remained stable
during the 24 h incubation at 2.50 and 13.97  0.98 mV, respectively (Figure 4-3A). The term
‘as is’ refers to non-desolvated gelatin solutions.
Impact of pH and incubation time on the gelatin solutions viscosity was studied with an intent
to understand the contribution of molecular forces in gelatin chains, and thus on the flowability of
the solutions (Figure 4-3B). The kinematic viscosity of 5%w/v ‘as is’ unadjusted gelatin solution
was 2.5 cSt and remained stable during the 24 h incubation. However, the viscosity of ‘as is’
adjusted gelatin solution was 3.40  0.03 cSt initially and declined quadratically by 27% to 2.48
 0.01 cSt after 24 h incubation. Likewise, the viscosity of adjusted desolvated gelatin solution
after 24 h incubation was 22% lower than the initial value. After pH adjustment, intramolecular
repulsive forces within gelatin chains coupled with intermolecular coulombic forces and hydrogen
bonding between gelatin chains might have led to high initial viscosities of adjusted gelatin
solution. Incubation presumably weakened the intermolecular forces due to high kinetic energy
and strengthened the intramolecular forces within gelatin chains. This rationalizes the quadratic
decline in the viscosities of adjusted gelatin solution to unadjusted values over 24 h incubation.
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Figure 4-3. [A] pH (---) and zeta potential (—) of ‘as is’ and desolvated 5 %w/v MedellaPro®
gelatin solutions as a function of incubation time; and [B] Kinematic viscosity of ‘as is’ and
desolvated 5 %w/v MedellaPro® gelatin solutions at 40°C as a function of incubation time. ‘As
is’ represents freshly prepared gelatin solutions that are not desolvated.
4.4.3

OFAT experiments

Preliminary investigation on the effect of gelatin solution pH and incubation times on GNPs
size and PDI were evaluated by OFAT approach.
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4.4.3.1.

Effect of gelatin solution pH on GNPs size and PDI

Impact of unadjusted and adjusted gelatin solutions on the critical quality attributes like size
and size distribution of GNPs engineered by two-step desolvation process was studied (Figure 44A-B).
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Figure 4-4. Size and polydispersity index of gelatin nanoparticles (GNPs) engineered by two-step
desolvation process: [A] using 0 h incubated unadjusted (pH 5.4) as well as adjusted (pH 2.5)
gelatin solutions; and [B] gemcitabine loaded active and corresponding placebo GNPs engineered
with 0 h incubation of adjusted (pH 2.5) gelatin solutions.
Size and PDI of the GNPs engineered using unadjusted gelatin solution were 1040.33 ± 19.76
nm and 0.672 ± 0.284, respectively. However, size and PDI of the GNPs engineered using adjusted
gelatin solution were 120.47 ± 1.69 nm and 0.060 ± 0.027, respectively. This suggests that adjusted
gelatin solution produces significantly smaller (p=0.0001) GNPs of narrow size distribution
(p=0.0206) than unadjusted gelatin solution (Figure 4-4A). The pH decreased to a point of

70

maximum net surface charge seems to increase the repulsive forces within gelatin chains and
prevent aggregation. Upon addition of the desolvating agent, these forces are presumably
dominated by intermolecular attractive forces between gelatin chains and resulted in smaller
GNPs. A similar trend in GNPs size variation by decreasing pH to 2.5 has been reported
previously.53, 154 However, few reports claim GNPs from type-A gelatin solution of pH below 3.5
show an increase in size58, or is totally unattainable61. This might be due to relatively lower
concentrations of gelatin solutions (1 %w/v) or desolvating agent (acetone) employed in
engineering GNPs. According to Shutava et al.58, type-A gelatin aqueous solution (5 %w/v)
showed peak zeta potential along with a sharp decline in viscosity at pH 3. The GNPs prepared at
this pH showed smaller size when compared to pH 4 and below pH 3, indicating gelatin solution
viscosity as an influencing factor on size. Ahsan and Rao61 observed a decreasing trend in size
until pH 4, for 1 %w/v type-A gelatin solution, and eventually claimed the unattainability of GNPs
below pH 3.5. However, our investigation clearly demonstrated the formation of nanosized GNPs
with narrow size distribution at pH 2.5.
We then studied the impact of drug loading on size and PDI of GNPs engineered using pH
adjusted gelatin solution by two-step desolvation process (Figure 4-4B). Generally, drug substance
loaded nanoparticles are expected to show larger size than corresponding placebos. The size of the
gemcitabine loaded active and corresponding placebo GNPs were 128.30 ± 0.95 nm and 128.03 ±
0.25 nm, respectively. The PDI of these active and placebo formulations were 0.048 ± 0.014 and
0.059 ± 0.002, respectively. We observed no significant (p>0.05) differences between the size and
PDI of the active and their corresponding placebo GNPs; suggesting gemcitabine loading did not
influence the size and PDI of GNPs. Therefore, we performed subsequent studies on placebo GNPs
using adjusted gelatin solutions.
4.4.3.2.

Effect of gelatin solution incubation time on GNPs size and PDI

Gelatin solution viscosity at a given pH, other than isoelectric point, either increases or
decreases with incubation time.147 Congruently, we found a quadradic decline in the viscosities of
both ‘as is’ and desolvated adjusted gelatin solutions during 24 h incubation (Figure 4-3B). Studies
have shown that the solution viscosity is influenced by gelatin molecular weight, concentration in
solution, solvent properties, temperature, and aging or incubation time.147, 155, 156 Additionally, the
rate of increase in viscosity was affected by the aging of the gelatin solutions at different pH
values.155 The basis for these viscosity changes were explained qualitatively by the changes in
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molecular shape of a gelatin caused by ionized functional groups.156 Based on these findings, we
hypothesized that the time allowed for gelatin solution to equilibrate at adjusted pH would instill
significant impact on the GNPs size and PDI. Thus, pH adjusted gelatin solutions were incubated
at 45°C for 0 h, 8 h, and 24 h, before engineering GNPs by one-step and two-step desolvation
processes, to investigate its effect on GNPs size and PDI.
One-step

Two-step

Size (nm)

600

*
**

400

**
200

0
0

8

24

Incubation time (h)

[A]

Polydispersity Index

0.80

0.60

0.40

0.20

*

0.00
0

8

24

Incubation time (h)

[B]

Figure 4-5. Impact of adjusted (pH 2.5) gelatin solution incubation time on gelatin nanoparticles
size [A] and polydispersity index [B] prepared by one-step and two-step desolvation process.
*p<0.05 and **p<0.01.
Irrespective of adjusted gelatin solution incubation times, one-step desolvation resulted in
significantly (p<0.05) larger GNPs than two-step desolvation. However, the influence of
incubation time on GNPs size was relatively dominant in one-step desolvation than two-step
desolvation (Figure 4-5). GNPs size by both one-step and two-step desolvation processes increased
with incubation time. GNPs engineered by one-step desolvation showed a significant 1.7-fold
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(p=0.0008) and 2.4-fold (p<0.0001) increase in size after 8 h and 24 h incubation, respectively,
when compared to 0 h incubation. Likewise, GNPs engineered by two-step desolvation showed a
significant 1.2-fold (p<0.0001) and 1.4-fold (p<0.0001) increase in size, respectively, when
compared to 0 h incubation.
Variability in size distribution of GNPs engineered by two-step desolvation process was
relatively smaller than one-step desolvation. Fresh adjusted gelatin solutions resulted in
significantly (p=0.0185) narrow sized GNPs from one-step desolvation than two-step desolvation.
However, the PDI difference between one-step and two-step desolvation processes after 8 h and
24 h incubation times remained statistically insignificant (p0.05). This is likely due to a difference
in the molecular weight distributions coupled with renaturation ability of gelatin with incubation
time.157
‘As is’ unadjusted gelatin solution comprises of a broader molecular weight distribution.53 First
desolvation step in the two-step desolvation results in the removal of low molecular weight gelatin
fraction. The sedimented high molecular weight fraction thus formed were presumed to contain
gelatin chains of relatively uniform length, which upon maximum protonation and controlled
desolvation resulted in uniform sized aggregates. Gelatin renaturation rate at pH 3 was reported to
increase exponentially with an increase in temperature from 20°C to 80°C.157 Furthermore, an
increase in kinetic energy with incubation time above gelation temperature increases the vibrations
of the gelatin chains and thereby its flexibility to renature.147 These vibrations presumably decrease
the intermolecular interactions and enhance intramolecular forces within gelatin polymeric chains
over time, and eventually led to a significant (p<0.05) increase in the GNPs size. On the contrary,
adjusted gelatin solution used in one-step desolvation process holds broad variability in gelatin
chain length due to broad molecular weight distribution. This might induce non-uniform inter- and
intra-molecular forces in gelatin chains, which upon desolvation might lead to less compact
mechanical entanglement.
Overall, increasing the pH incubation time of gelatin solution resulted in significantly (p<0.05)
larger GNPs with relatively consistent PDI due to a proportionate growth in the extent of
aggregation during desolvation.
4.4.4

Multivariate analysis

Multivariate analytical tools like PCA and PLS-1 regression were used to model the interplay
of desolvation steps, pH, and incubation time on GNPs size and PDI. The desolvation steps were
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coded as categorical variables and the remaining X-variables were evaluated as numeric
continuous data set.
4.4.4.1.

PCA

PCA score and loading plots were used to interpret qualitative relationships between the
multidimensional X and Y variables. The score plot (Figure 4-6A) suggests sample grouping,
similarities, and differences. While the loadings plot (Figure 4-6B) suggests factors responsible
for grouping in the score plot.151, 152

Figure 4-6. [A] Principal component analysis (PCA) score plot of gelatin nanoparticles prepared
with one- and two-step desolvation processes, using gelatin solutions up to 24 h pH incubation
times; [B] PCA loading plot of X-variable such as desolvation steps, gelatin solution pH, and
incubation time and Y-variables such as size and polydispersity index responsible for groupings
in the PCA score plot.
PCA used five principal components (PCs) to explain 100% variance in the data of which the
first two PCs explained 84.2% variance in the data. The score plot showed a clear separation of
GNPs engineered with one-step and two-step desolvation processes (Figure 4-6A). As expected
from traditional OFAT bi-variate analyses, GNPs engineered by one-step and two-step desolvation
exhibited a respective positive and negative correlation with size and PDI along PC1. Other Xvariables like pH and incubation time showed a positive correlation with size and PDI along PC1.
These correlations imply that one-step desolvation, pH, and incubation time would engineer larger
GNPs with relatively higher PDI compared to two-step desolvation. Additionally, the Eigen values
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of all variables (0.48) except PDI (0.26) were high along PC1, while gelatin solution incubation
time displayed high Eigen value (0.75) along PC2. Such high Eigen values indicate a statistically
significant impact of selected design variables on the important responses like size. However, a
low Eigen value, in the case of PDI, suggests significant differences could not be captured within
the studied experimental design space.
4.4.4.2.

Standard PLS-1 regression

After confirmation of statistically significant impact of selected design variables in PCA, a
quantitative relationship between these X-variables and one Y-variable at a time was computed
with PLS-1 regression method. Additionally, due to multidimensional nature of GNPs engineering,
impact of interactions and square effects of selected X-variables were also included in the
computed PLS-1 model. This could not be possible with a traditional OFAT analysis. Separate
PLS-1 models for size and PDI were developed for one-step and two-step desolvation processes.
The PLS-1 model was optimized as described previously.151, 152 Statistically significant variables
are characterized by 95% confidence interval bars not passing through the origin of the weighted
regression plots (Figures 7-8). A magnitude of impact of X-variable on Y-variable is displayed
with the height of the coefficient bars.
4.4.4.2.1

GNPs size

Equation 4-3 is the modeled regression equation to quantify the size of GNPs engineered by
one-step desolvation process. Two PCs were accumulated to obtain these regression coefficients
from the corresponding weighted regression plot (Figure 4-7A) and explain 100 % variance in
both X and Y data matrix. The first factor explained 90% and 79% of variance in X and Y data
matrix, respectively. Root-mean-square error (RMSE) at calibration and prediction stages for
Equation 4-3 were 18.54 nm and 27.82 nm, respectively. The model R2 values at the calibration
and at the prediction stage were 0.9724 and 0.9509, respectively.
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Figure 4-7. Weighted regression coefficients of gelatin nanoparticles size engineered by onestep [A] and two-step [B] desolvation methods.
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Table 4-1. Main effects along with calculated interaction and square terms used to predict gelatin nanoparticles size and
polydispersity index (PDI) using partial least square-1 model equation.

One − step size = −1039.3845 + 528.0936(pH) + 5.5613(incubation time) +

[4-3]

34.0604(pH ∗ incubation time) + 23.0562(pH)2 − 70.7555(incubation time)2
Equation 4-4 is the modeled regression equation to quantify the size of GNPs engineered by
two-step desolvation process. Two PCs were accumulated to obtain these regression coefficients
from the corresponding weighted regression plot (Figure 4-7B) and explain 100 % variance in both
X and Y data matrix. The first factor explained 89% and 74% of variance in X and Y data matrix,
respectively. RMSE at calibration and prediction stages for Equation 4 were 1.14 nm and 1.70 nm,
respectively. The model R2 values at the calibration and at the prediction stage were 0.9968 and
0.9942, respectively.
Two − step size = +349.92798 − 83.2227(pH) + 1.1125(incubation time) −

[4-4]

6.0204(pH ∗ incubation time) + 3.5649(pH)2 − 16.3055(incubation time)2
Correlations observed in PLS-1 regression analysis were concurrent with our OFAT and PCA
findings, along with previous reports.53 Table 4-1 shows the values of various interactions and
square terms. Size could be calculated by substituting these values in the Equations 3 and 4. The
significance of the model regression coefficients was measured using the Jack-Knifing method
and corresponds to p<0.05.
Equations 4-3 and 4-4 show statistically significant (p<0.05) positive and negative impacts of
the main effect of gelatin solution pH on the size of GNPs engineered with one-step and two-step
desolvation, respectively. Additionally, a positive impact of pH square effect was observed on the
GNPs size irrespective of the desolvation process (Equations 4-3 and 4-4). As elucidated earlier,
this could be attributed to the ionization of acidic and basic amino acids in gelatin chains that are
responsible for intra- and inter-molecular attractive and repulsive forces. Broad molecular weight
distribution of ‘as is’ adjusted gelatin solution results in a greater number of ionized functional
groups than desolvated adjusted form. This upon desolvation generates greater number of
intermolecular attractive forces necessary for dense and large particle entanglement than two-step
desolvation process. It is also important to note that the specific gravity of the one-step desolvated
GNPs was significantly (p<0.0001) higher than the two-step desolvated GNPs. This further
rationalizes the positive and negative impacts of pH on the GNPs size engineered by one-step and
two-step desolvation processes, respectively.
As observed in OFAT and PCA, incubation time in PLS-1 regression showed significant
positive correlation to size of GNPs engineered by one-step (Equation 4-3) and two-step (Equation
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4-4) desolvation processes. Size of GNPs engineered by both one-step and two-step processes
becomes linear with an increase in incubation time. However, such correlation diminishes in the
quadratic terms, suggesting optimum incubation time is critical to achieve GNPs of desired size
regardless of the desolvation process.
The incubation time of the gelatin solution and its interaction with pH showed a significant
(p<0.05) positive (Equation 4-3) and negative (Equation 4-4) correlation to the size of GNPs
engineered by one-step two-step desolvation processes, respectively. Two-way interactions are
observed when the changes in the variable levels and their corresponding effects are
interdependent. A positive interaction represents synergistic effect. Conversely, a negative
interaction indicates antagonistic effect.15 A positive interaction of pH and incubation time
interaction suggests that a higher pH along with longer incubation time could result in large size
of one-step desolvated GNPs. However, a negative interaction on the size of two-step desolvated
GNPs could be a function of relatively low intra- and inter-peptide interactions within the narrow
molecular weight distributed gelatin regardless of higher pH and longer incubation time.
4.4.4.2.2

GNPs PDI

PLS-1 regression model for the PDI of GNPs engineered by one-step desolvation was
statistically insignificant (p>0.05) within the studied experimental design space (Figure 4-8A).
PLS-1 regression model for the PDI of GNPs engineered by two-step desolvation process was
statistically significant (p<0.05) [Equation 4-5]. Two PCs were accumulated to obtain these
regression coefficients from the corresponding weighted regression plot (Figure 4-8B); and explain
100 % and 76% variance within X and Y data matrix, respectively. The first factor explained 90%
and 76% of variance in X and Y data matrix, respectively. RMSE at both calibration and prediction
stages was 0.01. The model R2 values at the calibration and at the prediction stage were 0.7554
and 0.6287, respectively. Main and square effects of incubation time in Equation 5 are statistically
insignificant (p>0.05). However, it is essential to incorporate these terms for better predictability
while computing the PDI of GNPs engineered by two-step desolvation process.152
Two − step PDI = −0.13053 + 0.0801(pH) − 0.0003(incubation time)† +

[5]

0.0033(pH ∗ incubation time) − 0.0034(pH)2 − 0.0047(incubation time)2†
†Statistically

insignificant variable

The pH along with its interaction with incubation time showed a significant (p<0.05) positive
impact on PDI. Additionally, squared term of gelatin solution pH showed a significant (p<0.05)
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negative impact on PDI. This corroborates our earlier justifications about the ionization of acidic
and basic amino acids with pH.

Figure 4-8. Weighted regression coefficients of gelatin nanoparticles size engineered by onestep [A] and two-step [B] desolvation methods.
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4.4.5

Preliminary stability studies

In-process and finished product physical stability are critical to ensure the quality and safety
of the pharmaceutical products. GNPs engineered by desolvation are sometimes subjected to freeze
drying before storage.54, 55, 57-59, 61 To our knowledge, the impact of freezing step in lyophilization
process on the GNPs physical stability has not been reported in the literature. Such freezing
temperatures could instill a severe stress on the protein solutions. GNPs engineered by two-step
desolvation using fresh adjusted gelatin solution were selected for a preliminary stability analysis
due to their relatively small size and narrow distribution over one-step desolvation process. GNPs
were subjected to one freeze-thaw cycle and analyzed for size and PDI for 30 days (Figure 4-9).
Freeze-Thawed

Ambient
400

*

Size (nm)

300

*
*

200

*

*

100

0
0

2

3

7
14
Time (Day)

21

30

21

30

[A]

Polydispersity Index

0.10
0.08
0.06
0.04
0.02
0.00
0

2

3

7

14

Time (Day)

[B]

Figure 4-9. Size [A] and polydispersity index [B] of two-step desolvated gelatin nanoparticles
(GNPs) engineered using 0 h incubated adjusted (pH 2.5) gelatin solution and stored at ambient
conditions for 30 days. GNPs subjected to the freeze-thawing were initially exposed to -80°C for
5 h and thawed at ambient condition for 1 h before analyzing at respective time-points. *p<0.001.
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The size of freeze-thawed GNPs ranged between 139.4  0.9 nm and 336.2  9.1 nm over 30
days. On the other hand, size of GNPs stored at ambient conditions, without freeze-thawing,
ranged between 145.5  0.9 nm and 157.1  2.0 nm over 30 days. The size of freeze-thawed GNPs
(139.4  0.9 nm) on day 0 was significantly (p=0.0009) lower than the non-freeze thawed GNPs
(145.5  0.9 nm). However, freeze-thawed GNPs showed 2.4-fold increase in size after 30 days
storage at ambient conditions. On the contrary, non-freeze thawed GNPs showed 1.1-fold
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Figure 4-10. Size and polydispersity index of gelatin nanoparticles engineered by two-step
desolvation method using 0 h incubated gelatin solution and stored at ambient conditions for 265
days.
PDI less than 0.2 is generally considered monodisperse and ideal for polymeric nanoparticles.
The PDI of both freeze-thawed and non-freeze thawed GNPs were less than 0.10 and showed no
significant differences at respective time points (p>0.05). This demonstrates that GNPs size
distribution was not affected by freeze-thaw treatment throughout 30 days duration. Additionally,
exposure of non-freeze thawed GNPs to ambient conditions for 265 days resulted in 1.3-fold
significant increase (p<0.0001) in size without any significant change in the PDI (p<0.7207; Figure
4-10).
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Figure 4-11. Size and polydispersity index of gelatin nanoparticles engineered by one-step [A; B]
and two-step desolvation processes [C; D] using adjusted (pH 2.5) gelatin solution at varied
incubation times and stored at ambient conditions for 238 days. *p<0.05, **p<0.01, and
***p<0.0001.
Figure 4-11 shows the size of one- and two-step desolvated GNPs, engineered with pH adjusted
gelatin solution incubated for 0, 8, and 24 h, for 238 days. It is interesting to note that the incubation
time of adjusted gelatin solution showed a notably (p<0.05) significant impact on the GNPs
engineered by one-step desolvation than two-step desolvation process. Furthermore, irrespective
of incubation times, GNPs from two-step desolvation maintained better physical stability in terms
of size and size distribution than one-step desolvation.
4.5.Conclusion
We demonstrated the decisive implications of gelatin solution pH and incubation time on GNPs
size and size distribution. Regarding GNPs engineering procedure, desolvating a gelatin solution
with maximum net charge at pH 2.5 produced smaller GNPs with narrow size distributions. This
delineates the importance to understand the gelatin solution pH—surface charge profile before
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engineering GNPs by desolvation. Irrespective of the desolvation procedure, prolonged pH
incubation time significantly increased GNPs size and demonstrated modest impact on size
distributions. This phenomenon was particularly evident in GNPs engineered from one-step than
two-step desolvation processes. Hence, GNPs from one-step desolvation were relatively larger in
size than two-step desolvation, with conspicuous difference in their size distributions. Apart of
traditional OFAT analysis, the interplay of gelatin solution pH and incubation times on GNPs size
and PDI were statistically elucidated by PCA and PLS-1 multivariate tools. Significant predictive
model equations to compute the impact of main effects, interactions, and square effects on GNPs
size and PDI were derived and verified. Essentially, our findings establish gelatin solution pH and
incubation time as a high-risk critical process parameter impacting the critical quality attributes of
GNPs regardless of the desolvation processes. Therefore, it is highly recommended to use a freshly
prepared gelatin solution with consistent processing times and clearly define the parameter in the
manufacturing process to attain GNPs of reproducible size. Overall, our investigation underlined
the importance of handling the starting material to establish reproducible manufacturing
procedures and engineer protein-based polymeric nanoparticles of consistent physicochemical
properties.
4.6.Funding
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Chapter 5 : FORMULATION AND PROCESS VARIABLES IMPACTING
REPRODUCIBILITY IN GELATIN NANOPARTICLES ENGINEERED BY
DESOLVATION
Abstract
Gelatin nanoparticle (GNPs) that are amenable to carry small molecules and
biopharmaceuticals. However, their translation to clinic is plagued by reproducibility challenges
due to complex variability within the gelatin as a starting material. Therefore, this study was
designed to: (i) demonstrate initial desolvation of ‘as is’ gelatin as a strategy to minimize
variability within starting material; and (ii) screen the impact of ‘as is’ and desolvated forms of
various gelatin grades along with other critical formulation as well as process variables on size,
size distribution, and surface charge of GNPs by Definitive screening design. Gel electrophoresis
indicated 20-40% elimination of the low molecular weight (25 kD) fraction by a desolvating ‘as
is’ gelatin with acetone. Definitive screening design showed a significant influence of gelatin type
(p=0.0287) and gelatin solution concentration (p=0.0164) on the size of the GNPs. Additionally,
gelatin solution pH showed a significant (p=0.0011) negative correlation to surface charge on
GNPs. Our findings demonstrated the initial desolvation of gelatin would minimize grade-to-grade
variability of gelatin in terms of molecular weight distribution. Stability studies suggests that most
GNP formulations from the screening design maintained their size and size distribution for 4 weeks
at ambient conditions.
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5.1.Introduction
Gelatin has been an extensively investigated biodegradable natural protein to deliver smalland macro-molecules.4 It is due to the ability of gelatin to dissolve in aqueous milieu and undergo
temperature dependent gel-sol transitions that allows for the encapsulation of various materials.45,
50, 51

This coupled with Generally Regarded as Safe (GRAS) designation for gelatin158 by the US

FDA have been the driving factors for researchers to explore gelatin as a potential carrier for drug
delivery.
Several processes have emerged to engineer GNPs that are amenable to carry small molecules
and biopharmaceuticals. Among them, desolvation methods are widely used to engineer GNPs.37,
53, 54

One-step desolvation was the first reported process to engineer GNPs of larger size and broad

size distribution.37 However, the process is plagued by non-uniform aggregate formation before
and after crosslinking due to heterogeneity in the gelatin molecular weight. Coester et al. 53
introduced a second desolvation step before crosslinking to generate relatively uniform sized
particles with narrow size distribution. Ofokansi et al.54 developed a simplified one-step
desolvation process owing to the tediousness associated with the above two processes. It involves
pH adjustment of gelatin aqueous solution to neutral values before desolvation to impart a net
charge on gelatin. The charge would induce intra- and inter-molecular forces in gelatin chain,
thereby leading to controlled entanglement of the protein fragments to form uniform sized
nanoparticles.
Desolvation process as a whole involves the dissolution of gelatin and drug substance in an
aqueous solvent, followed by the controlled addition of an organic solvent to obtain nanoparticles.
Aqueous gelatin solution comprises of gelatin and an aqueous solvent bound by hydrogen bonding.
Addition of a desolvating agent viz., ethanol or acetone, initiates the breakdown of these hydrogen
bonds and replace water molecules surrounding the gelatin with a desolvating agent. This
eventually leads to folding or restructuring of gelatin fragments into aggregate structures. The
gelatin aggregates, thus formed, are ultimately crosslinked with a chemical crosslinker to instill
physical stability in the particles.
In vivo degradation and cellular uptake of nanoparticles by endocytosis are influenced by size
and size distribution.61 Previous studies have shown size modulations in the desolvation procedure
due to various reaction parameters such as desolvation steps 53, gelatin type55-59, gelatin
concentration60, gelatin solution pH54, 55, 57-59, 61, desolvating agent type55, 56, amount of desolvating
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agent61, temperature55, 57, crosslinker concentration54, 55, 62, and crosslinking time54. However, to
our knowledge, studies elucidating the impact of desolvation rate, temperature and mixing speed
on size and size distribution have not been reported.
Despite decades of research, no gelatin nanoparticles (GNPs) product has reached the clinic.
Inability of gelatin to produce GNPs with consistent physicochemical properties has presumably
decreased its translation potential. We hypothesize that this is due to complex variability within
the gelatin as a starting material.
Therefore, the objectives of this investigational study is to: (i) demonstrate initial desolvation
of ‘as is’ gelatin as a strategy to minimize variability within starting material; (ii) screen the impact
of ‘as is’ and desolvated forms of various gelatin grades along with other critical formulation as
well as process variables on size, size distribution, and surface charge of GNPs by Design of
Experiments; and (iii) monitor the physical stability i.e., size and size distribution of engineered
GNPs stored in ambient conditions for 4 weeks.
Reported manufacturing processes37,

53, 54

have been slightly modified to understand the

implications of starting material along with other formulation as well as process variables in a
single study design. Sildenafil citrate was used as a model drug substance. Acetone was used to
desolvate ‘as is’ gelatin to minimize variability within the starting material. However, ethanol was
used as desolvating agent to engineer GNPs as it is clinically approved by the FDA for parenteral
administration.159 Genipin was used as a crosslinker as it is derived from natural source and has
shown to be 10000-times less cytotoxic than commonly used glutaraldehyde.148
5.2.Materials
Type A porcine skin gelatin ~175 g Bloom (Catalog no. G2625; Lot No. SLBT2992) and Type
B bovine skin gelatin (~225 g Bloom; Catalog no. G9382; Lot No. SLCB6022) were purchased
from Sigma–Aldrich (St. Louis, MO, USA). For the ease of illustration, ‘Type-A’ and ‘Type-B’
gelatins from Sigma–Aldrich will be presented throughout this chapter as ‘Sigma-A’ and ‘SigmaB’ respectively. MedellaPro® (~191 g Bloom; Lot no. 7323-2C) and Rousselot® 195 AH 18/60
grades of gelatin were obtained as gift samples from Gelita (Sergeant Bluff, IA, USA) and
Rousselot (Dubuque, IA), respectively. Sildenafil citrate, USP (Catalog no. S3092; Lot no.
1IF0408) was purchased from Spectrum Chemicals (New Brunswick, NJ, USA). Genipin (Catalog
no. 078-03021; Lot no. WEE4931) were purchased Wako Pure Chemical Industries Ltd (Osaka,
Japan). Ethanol (200 proof; Catalog no. 2701; Lot no. 151812) was purchased from Decon
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Laboratories Inc (King of Prussia, PA, USA). Hydrochloric acid [HCl] (12.1N; Catalog no. A144;
Lot no. 171938) and sodium hydroxide [NaOH] beads (ACS grade; Catalog no. BHD0292; Lot
no. 97821) were procured from Fisher Chemicals (Hampton, NH, USA) and VWR International
LLC (West Chester, PA, USA), respectively.
5.3.Methods
5.3.1. Gelatin Solution pH and Zeta Potential
The pH of gelatin solutions were adjusted, and the zeta potential at a given pH was determined
as mentioned section 4.3.2.
Briefly 1.00 g of ‘as is’ gelatin was dissolved in 100 mL MilliQ ® water at 40±2°C and 300 rpm
mix speed for 20 min. Solution was adjusted to desired pH 1.0 N HCl or 1.0 N NaOH solutions
under constant mixing. The pH was measured using a Seven Compact pH meter (Mettler Toledo
LLC, Columbus, OH) equipped with InLab® Expert Pro-ISM (Order no. 30014096), calibrated
and verified as per the United States Pharmacopoeia <791>149.
Zeta potential was measured using a Zetasizer Nano-ZS (Malvern Instruments Ltd.,
Worcestershire, UK). Exactly 5 min after pH adjustment, solution was loaded into a disposable
folded capillary cell (Catalog no. DTS1070) and equilibrated at 37.0±0.2°C for 60 s. Each solution
was then measured in triplicate in which a measurement was an average of 50 scans. Raw data was
processed using Malvern Zetasizer v7.12 software (Malvern Instruments Ltd., Worcestershire,
UK).
5.3.2. Preparation of desolvated gelatin

Figure 5-1. Schematic illustration of desolvated gelatin preparation
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Figure 5-1 provides a schematic illustration of desolvated gelatin preparation. Briefly, 5 g of
‘as is’ gelatin was dissolved in 100 mL MilliQ ® water at 45±2°C and mixed for ~15 min.
Accurately, 100 mL acetone was added to the homogenous gelatin aqueous solution and
concoction was allowed to mix for ~2 min, followed by ~1 min resting at room temperature. The
supernatant was discarded and the precipitate which was considered high molecular weight gelatin
fraction was carefully collected, cut to small pieces, and dried at room temperature for ~24 h before
use.
5.3.3. Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE)
SDS-PAGE was performed using Mini-PROTEAN® Tetra system (Bio-Rad, Hercules, CA,
USA) with 4-20% TGXTM precast polyacrylamide protein gels (Part no. 4561093; 8.6 cm width x
6.7 cm length). Gelatin samples were dissolved in water and denatured according to
manufacturer’s instructions. KaleidoscopeTM protein ladder (Catalog no. 161-0375; Bio-Rad,
Hercules, CA, USA) was used as control to monitor protein separation and estimate the protein
molecular weight of the samples. Approximately 75 g gelatin was loaded per well and run at 60
V for 15 min followed by 120 V for 90 min in 1x Tris-Glycine SDS running buffer. Gels were
stained with Coomassie® R-250 prior to imaging in ChemiDoc. Band equivalent to 25kD in control
were analyzed using free Image StudioTM Lite software (Li-Cor® Biosciences, USA) to predict
desolvated percent of ‘as is’ gelatin.
5.3.4. GNPs preparation
Sildenafil citrate loaded GNPs were prepared by one-step desolvation process, using
previously developed unit operation (Figure 4-1) by slight modification in the formulation
procedure.160
Gelatin of desired grade as well as type was weighed and dissolved in 10 mL of MilliQ ® water
at desired desolvation temperature. Aqueous sildenafil citrate solution (1 mg/mL) was substituted
for MilliQ® water in case of active GNPs. Under constant mixing at ~500 rpm, the solution was
equilibrated for ~15 min at desired temperature to form a homogenous solution. The solution pH
was determined and adjusted to desired value using 1.0 N HCl or 1.0 N NaOH solutions. The pH
adjusted solution was transferred to a mobile phase glass bottle (100 mL capacity) to engineer
GNPs.
In order to achieve desolvation, desired amount of ethanol was added at desired rate using a
syringe pump (Model no. 300; New Era Pump Systems Inc.) and 60 mL plastic syringe (Reference
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no. 309654; Becton Dickinson syringes). After cooling to room temperature in 30 min, 500 L of
ethanol was added at 0.1 mL/min using 5 mL BD plastic syringe. In formulations that required
genipin crosslinker, desired amount was added as ethanolic solution. Subsequently, the engineered
GNPs were stored at ambient conditions for further studies.
5.3.5. Experimental design
A definitive screening design was used to identify the critical individual effects of the input
parameters. Table 5-1 summarizes the list of all the factors and the levels used to generate the
design using JMP®v13 statistical software (SAS Institute, Cary, NC). Table 5-2 summarizes the
runs generated within the experimental domain of definitive screening design. The ratio of gelatin
to genipin was held constant at 500:1 w/w in all the experiments. Analysis for particle size, span,
zeta potential, and entrapment efficiency were executed to identify significant material and process
variables.
Table 5-1. Screening design variables
Factors
Levels
Gelatin grade
Sigma-A
Sigma-B
MedellaPro®
Rousselot®
Gelatin type
As is
Desolvated
Gelatin concentration
0.5 %w/v
5.0 %w/v
Sildenafil citrate amount1
0 mg
10 mg
Gelatin solution pH
3.5
7.0
Desolvating agent
30%v/v
80%v/v
Desolvation rate
1 mL/min
5 mL/min
Desolvation temperature
37C
50C
Mixing speed
300 rpm
700 rpm
2
Genipin concentration
0 %w/w
0.02 %w/w
1
Added in the form of solution; 2Expressed as the percent weight of gelatin
5.3.6. Size and Zeta potential
Size, size distribution, and zeta potential measurements were performed using a Zetasizer
Nano-ZS (Malvern Instruments Ltd., Worcestershire, UK).
For size and size distribution, about 50 mL GNPs formulation in disposable cuvette (Catalog
no. ZEN0040) was equilibrated at 25.0±0.2°C and measured at 173° backscattering, 0.001
absorption, and 0.8872 cP viscosity. Protein and water were chosen as material and dispersant,
respectively. Each measurement was an average of 30 scans with 5 s scan time and automatic
attenuation. Raw data was processed using Malvern Zetasizer v7.12 software (Malvern
Instruments Ltd., Worcestershire, UK).
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Table 5-2. Definitive screening design with actual run conditions substituted under respective factors
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5.3.7. Entrapment efficiency
GNPs dispersion was subjected to ultracentrifugation (Optima MAX-XP; Beckman Coulter,
Inc.) with MLA-55 rotor at 50,000 rpm and 22±1°C for 30 min, in OptiSeal® ultracentrifugation
tubes (8.9 mL; Reference no. 361623, Beckman Coulter). Supernatant containing the dissolved
free drug was quantified in HPLC to determine the entrapment efficiency (Eq. 5-1)
Entrapment efficiency (%) = (1 −

mass of SC in the supernatant
) x100
mass of SC used in the formulation

5.3.8. High-pressure liquid chromatography
The United States Pharmacopoeia (USP) sildenafil citrate assay method was verified and used
to quantify the amount of sildenafil citrate in the SC-loaded GNP formulations. A high-pressure
liquid chromatography (HPLC) equipped with Waters Alliance®2695 separation module (Part
#WAT270886, Waters Inc., Milford, MA), and 996-photodiode array detector (PDA) [Part
#WAT057002, Waters Inc., Milford, MA USA].
Standard and sample solutions were diluted in buffer:methanol:acetonitrile (58:25:17 v/v) that
was used as the mobile phase. Triethylamine-phosphate solution (pH 3.0±0.1) was used as the
buffer. It was prepared by diluting 7 mL of triethylamine (Catalog no. 89500-558, VWR) with
MilliQ® water to 1000 mL and adjusting with o-phosphoric acid (ACS grade, Catalog no. A242500; Fisher Scientific) to pH 3.0±0.1.
Before analysis, a freshly prepared mobile phase was pumped at 1 mL/min though HPLC for
~30 min to equilibrate the system. The autosampler and column heater were operated at 22±3°C
and 30±2°C, respectively. Separation was achieved using Symmetry ®C18 (150 x 39 mm, 5µm;
Part no. WAT046980) column from Water Corp. The method run time and the injection volume
were 15 min and 20 µL, respectively. Data was collected and analyzed using Empower ® Pro
software v3 at 290 nm detection wavelength.
5.3.9. Preliminary stability studies
All the screening design formulations, stored at ambient room temperature, were monitored
for size and PDI every week for a month.
5.3.10. Statistical analysis
Where ever applicable, sample means were compared by Student t-test, or one-way analysis
of variance (ANOVA) followed by post-hoc test. In Student t-test, Welch’s test was used when
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the variance between two samples was unequal. A p-value of <0.05 was considered statistically
significant.
5.4.Results and Discussion
5.4.1. Effect of pH on gelatin solution zeta-potential
As elucidated in section 4.4.1, zeta potential is an indicator of the net surface charge of a gelatin
molecule in a dispersion. It is critical to understand the correlation between gelatin solution pH
and zeta potential to engineer GNPs of desired size and size distribution.
The pH of all four investigated gelatin grades at 1%w/v concentration was 5.35  0.08. The
surface charge of freshly prepared 1%w/v solutions of Sigma-A and MedellaPro® gelatin grades
were 4.98  0.12 mV and 5.56  0.10 mV, respectively. However, the surface of Sigma-B and
Rousselot® gelatin grades were relatively lower at -0.45  0.07 mV and 2.86  0.32 mV,
respectively.
30
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Figure 5-2. pH—surface charge profiles of Sigma-A, MedellaPro®, Sigma-B, and Rousselot®
grades of gelatin solution at 1%w/v concentration in MilliQ® water.
Figure 5-2 illustrates the pH—surface charge distribution profiles of various gelation grades.
Gelatins obtained by acid hydrolysis of collagen usually show zero net surface charge in alkaline
conditions i.e., pH 7.0-9.0. However, gelatins from alkaline hydrolysis usually show zero net
surface charge in acidic conditions i.e., pH 4.5 to 5.5. It is the pH of the gelatin solution where the
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molecule carries equal number of -COO− and -NH3+ ions, and do not undergo migration in an
electric field. Zero surface charge of Sigma-A and MedellaPro® gelatin grades at 7.8 pH suggests
they are obtained by partial acid hydrolysis of collagen. Likewise, zero surface charge of SigmaB and Rousselot® gelatin grades at 5.5 pH suggests they are obtained by alkaline hydrolysis of
collagen. At pH resulting in zero net surface charge, the attractive forces exceed repulsive forces
and leads to aggregation of gelatin molecules.
From pH 3.5, the degree of deprotonation with increase in pH 5 is low in Sigma-A and
MedellaPro® grades when compared to Sigma-B and Rousselot® grades (Figure 5-2). It resulted
in 5 mV net negative charge in Sigma-B and Rousselot® gelatin grades at pH 7.0 while the net
charge is 0 mV in Sigma-A and MedellaPro® gelatin grades.
5.4.2. Low molecular weight fractions
The primary structures of ‘as is’ and desolvated forms of MedellaPro ®, Rousselot®, Sigma-A
and Sigma-B gelatin grades were observed by SDS-PAGE (Figure 5-3[A]). Migration of these
bands i.e., protein pattern in the gel is dependent on protein molecule weight. Protein patterns are
similar in ‘as is’ and desolvated forms of all gelatin grades. However, the band intensities appear
different between ‘as is’ and desolvated forms, especially at 25 kD lower molecular weight
regions. In all gelatin grades, ‘as is’ forms show slightly higher band intensity than corresponding
desolvated forms.
For quantitative comparison, the intensity of 25 kD band in desolvated gelatin was compared
to corresponding ‘as is’ form for each gelatin grade (Figure 5-3[B]). This relative numeric was
used as an estimate for the proportion of 25 kD molecular weight protein band. Desolvated TypeA gelatin grades i.e., MedellaPro® and Sigma-A showed 80.7910.37% and 68.195.48% of 25
kD gelatin molecular weight band compared to their ‘as is’ forms, respectively. Desolvated TypeB gelatin grades i.e., Rousselot® and Sigma-B showed 76.784.33% and 61.763.54% of 25 kD
gelatin molecular weight band compared to their ‘as is’ forms, respectively. The proportion of
25kD band is significantly (p=0.0292) lower in Sigma-B grade compared to MedellaPro®. Such
significant differences were not observed among other investigated gelatin grades.
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[A]

[B]
Figure 5-3. [A] Representative SDS-PAGE patterns of various ‘as is’ and desolvated (Des) forms
of MedellaPro®, Rousselot®, Sigma-A, and Sigma-B gelatin grades. ‘Control’ represents the
molecular weight marker. [B] Overlay of percent low molecular weight (LMW), 25kD, fraction in
the desolvated forms of various gelatin grades when compared to ‘as is’ forms.
Overall, about 20-40% of the low molecular weight (25 kD) gelatin could be eliminated by a
single desolvation step using acetone. This supports the findings of our own 160 and in literature53,
56.

Desolvation of ‘as is’ gelatin precipitates high molecular weight fraction and narrows the
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molecular weight distribution. With controlled desolvation process, the desolvated gelatins would
produce GNPs of uniform size and narrow size distribution.
5.4.3. Definitive Screening Design
Table 5-3 summarizes the size, PDI, zeta potential, entrapment efficiency of GNPs engineered
using variables within the experimental domain of the definitive screening design (Table 5-2).
Table 5-3. Size, polydispersity index and zeta potential (n=3) of gelatin nanoparticle formulations.
‘-NA-’ represents not applicable
Entrapment
Formulation
Size (nm)
PDI
Zeta potential (mV)
efficiency (%)
F-1
-NA633.00  14.29
0.214  0.014
(+) 35.90  4.30
F-2

92.99  0.22

0.147  0.015

(+) 31.83  11.47

-NA-

F-3

94.48  1.32

0.192  0.013

(+) 35.83  3.16

0

F-4

279.40  11.93

0.996  0.007

(-) 10.33  0.12

0

F-5

107.37  6.27

0.765  0.124

(-) 24.87  1.75

-NA-

F-6

2136.33  198.53

0.892  0.154

(-) 22.47  0.72

0

F-7

940.60  27.85

0.542  0.029

(+) 31.93  2.30

0

F-8

632.37  9.16

0.109  0.048

(-) 31.63  0.93

-NA-

F-9

216.17  1.27

0.295  0.017

(-) 8.10  0.86

5.21%

F-10

237.40  1.39

0.042  0.019

(-) 29.17  1.24

0

F-11

412.00  4.69

0.582  0.057

(+) 34.10  0.95

4.62%

F-12

290.53  4.37

0.199  0.024

(+) 28.50  0.30

-NA-

F-13

499.27  8.79

0.056  0.016

(-) 21.10  0.56

-NA-

F-14

483.87  1.40

0.043  0.025

(+) 18.37  0.35

0

F-15

4000  0.00

1.000  0.000

(-) 1.05  0.21

-NA-

F-16

3587.33  645.71

0.317  0.194

(+) 20.17  0.83

-NA-

Results showed that the size varied from 92 nm to 4000 nm, PDI varied from 0.04 to 1.00,
and zeta potential varied from -31 mV to +36 mV. The degree of variability in the response
variables affects the confidence of statistical analysis. Broad range in response variables suggests
that the levels of independent variables selected in the experimental design space were wide
enough to map the experimental domains. This is not the case with entrapment efficiency for two
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reasons: (i) half of the formulations are placebos; and (ii) one-third of the sildenafil citrate loaded
formulations showed no entrapment.

[A]

[B]

[C]
Figure 5-4. Actual by prediction plots for [A] Size expressed as Z-average [B] polydispersity
index (PDI), and [C] Zeta potential.
Figure 5-4 and Table 5-4 shows the ANOVA results of size, PDI, and zeta potential for the
GNPs from definitive screening design. Entrapment efficiency could not be analyzed due to
narrow range in response variables as outlined above. Model for zeta potential (p=0.0249, adjusted
R2=0.9145, RMSE=7.71) was statistically significant. However, no statistically significant models
could be generated for size (p=0.0705, adjusted R2=0.8225, RMSE=517.94) and PDI (p=0.3780,
adjusted R2=0.3395, RMSE=0.282). The adjusted R2 is used as an estimate of model predictability.
Root mean square error (RMSE) is used as an estimate of standard deviation of the random error.
It is a good predictor of how accurately the model predicts the response.
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Table 5-4. Analysis of variance results for the employed definitive screening design in the
development of gelatin nanoparticles
Size (nm)

Responses
Factors

PDI

Zeta potential (mV)

F-value

p-value

F-value

p-value

F-value

p-value

Gelatin grade

6.81

0.0747

1.23

0.4350

2.28

0.2576

Gelatin type

15.71

0.0287*

0.06

0.8236

0.26

0.6468

Gelatin concentration

23.57

0.0167*

2.56

0.2078

0.45

0.5493

Sildenafil citrate amount1

5.92

0.0930

0.48

0.5396

0.16

0.7157

Gelatin solution pH

0.58

0.5028

2.90

0.1874

156.10

0.0011*

Desolvating agent

7.59

0.0704

7.24

0.0744

4.81

0.1159

Desolvation rate

0.01

0.9397

2.04

0.2489

0.07

0.8064

Desolvation temperature

0.13

0.7443

0.58

0.5019

2.76

0.1952

Mixing speed

6.44

0.0848

0.18

0.7001

0.81

0.4346

Genipin concentration2

1.10

0.3719

0.00

0.9870

0.22

0.6714

1Added

in the form of solution; 2Expressed as the percent weight of gelatin

Despite insignificant model, trends were observed for size. Gelatin type (p=0.0287) and
concentration (p=0.0164) significantly influenced the size of the GNPs. Desolvation of high
concentration gelatin solution resulted in larger size. Koletti et al reported similar observation.56
Additionally, the extent of increase was high in ‘as is’ forms of gelatin than their desolvated forms.
This is concurrent with our previous work.160 Surprisingly, gelatin solution pH did not show any
significant influence on size.53,

154, 160

No independent variables (Table 5-4) were found to

significantly (p>0.05) influence the PDI.
A decrease in gelatin solution pH significantly (p=0.0011) increases the zeta potential. The pH
decreased to 3.5 increases the net positive charge due to protonation of -COO− as well as -NH2
functional groups in gelatin, and results in GNPs with a net positive charge. The opposite is the
case with pH 7.0 gelatin solution.
Data set from definitive screening design were further analyzed by Principal Component
Analysis (PCA). The data set requires 11 principal components to explain 100% of variance in the
data set. First two principal components explained 37.98% of the variance in the data. Score plot
(Figure 5-5) shows a classifiable grouping of definitive screening design formulations based on
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the pH of the gelatin solution used to engineer GNPs (Table 5-2). This suggests the criticality of
gelatin solution pH in the determining the quality and performance of GNPs.

Figure 5-5. Score plot of screening design formulations. GNPs engineered using pH 3.5 gelatin
solutions are highlighted in red whereas the formulations from pH 7.0 gelatin solutions are
highlighted in blue.
5.4.4. Stability of screening design formulations
Most of the GNP reports in the literature are focused on developing efficient carriers of drug
substance. However, their physical and chemical stability that is critical to ensure the quality and
safety are often disregarded.
Size (Figure 5-6) and PDI (Figure 5-7) of the formulations from definitive screening design
were monitored for 4 weeks at ambient conditions.
Size of GNPs stored at ambient conditions ranged between <100 nm to >4000 nm. The size
and PDI of F15 as well as F16 formulations were >4000 nm and 1.0, respectively. Furthermore,
they transformed to gel over time. This could be due to excess agglomeration triggered by high
concentration of gelatin and less amount of desolvating agent while using ‘as is’ type of gelatin.
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Hence, they are ignored for further analysis. Size of the remains formulations F01 to F14 remained
relatively stable for 4 weeks. This is concurrent to our previous findings in two-step desolvated
GNPs engineered using 0 h incubated pH 2.5 gelatin solution.160 Potential side-effects associated
with parenteral administration viz., thrombosis and embolism can be avoided by delivering
nanoparticles of <500 nm.161-163 However, considering logistics in downstream manufacturability
and scale-up, a size of 200 nm would be ideal. Yield would not be impacted when nanoparticles
under this size range are subjected to terminal sterilization of nanoparticle dispersion by filtration
technique. F02, F03, and F05 among the engineered GNPs fall under this category.

Figure 5-6. Size of gelatin nanoparticle formulations from definitive screening design stored at
ambient conditions for 4 weeks. Red dash-line indicate 500 nm and green dash-line indicates 200
nm.
PDI of GNPs stored at ambient conditions ranged between 0.1 to 1.0. A PDI of 0.3 in lipid
nanoparticle populations is considered to be acceptable when intended for parenteral
administration.164 To authors knowledge, desired PDI value in polymeric nanoparticle
formulations for parenteral administration is nowhere reported in literature. Therefore, PDI of
0.2 has been chosen in our study for two reasons: (i) particles under this value are generally
considered monodisperse; and (ii) minimizes impact on yield after terminal sterilization process
by filtration. F02, F03, F08, and F10 formulations showed a PDI values feasible to sustain terminal
sterilization process.
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Figure 5-7. Polydispersity index (PDI) of gelatin nanoparticles from definitive screening design
stored at ambient conditions for 4 weeks. Red dash-line indicate 0.3 and green dash-line indicates
0.2.
5.5.Conclusion
A new strategy to produce solid mass of desolvated gelatin as starting material for the
development of GNPs was successfully developed. SDS-PAGE demonstrated that the initial
desolvation of gelatin minimizes grade-to-grade variability of gelatin, in terms of molecular weight
distribution. Quality and performance of the GNPs are critically determined gelatin solution pH
used to engineer nanoparticles. Size and PDI of most GNP formulations from the screening design
remained stable for 4 weeks at ambient conditions. Overall, our investigation underlined the
importance of processing the starting material to establish reproducible manufacturing procedures
and opened doors to engineer gelatin-based polymeric nanoparticles of consistent physicochemical
properties.
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